US20210177620A1 - Porous composite biomaterials and related methods - Google Patents
Porous composite biomaterials and related methods Download PDFInfo
- Publication number
- US20210177620A1 US20210177620A1 US17/180,935 US202117180935A US2021177620A1 US 20210177620 A1 US20210177620 A1 US 20210177620A1 US 202117180935 A US202117180935 A US 202117180935A US 2021177620 A1 US2021177620 A1 US 2021177620A1
- Authority
- US
- United States
- Prior art keywords
- polymer
- particles
- composite material
- scaffold
- reinforcement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 120
- 238000000034 method Methods 0.000 title claims description 53
- 239000012620 biological material Substances 0.000 title description 9
- 239000002245 particle Substances 0.000 claims abstract description 85
- 229920000642 polymer Polymers 0.000 claims abstract description 72
- 230000002787 reinforcement Effects 0.000 claims abstract description 71
- 239000011148 porous material Substances 0.000 claims abstract description 61
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 52
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 51
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 40
- 239000000463 material Substances 0.000 claims abstract description 40
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 37
- 239000011800 void material Substances 0.000 claims abstract description 23
- 229920006260 polyaryletherketone Polymers 0.000 claims abstract description 22
- 210000000988 bone and bone Anatomy 0.000 claims description 50
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 48
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 46
- -1 polyethylene Polymers 0.000 claims description 40
- 239000000843 powder Substances 0.000 claims description 26
- 239000003361 porogen Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 22
- 229920001169 thermoplastic Polymers 0.000 claims description 22
- 239000004696 Poly ether ether ketone Substances 0.000 claims description 18
- 229920002530 polyetherether ketone Polymers 0.000 claims description 18
- 238000000748 compression moulding Methods 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 10
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 6
- ZBZJARSYCHAEND-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydrate Chemical compound O.[Ca+2].OP(O)([O-])=O.OP(O)([O-])=O ZBZJARSYCHAEND-UHFFFAOYSA-L 0.000 claims description 6
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 6
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 6
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium phosphate dihydrate Substances O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 claims description 6
- 238000002386 leaching Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229910000150 monocalcium phosphate Inorganic materials 0.000 claims description 6
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 6
- 229910000392 octacalcium phosphate Inorganic materials 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229920001903 high density polyethylene Polymers 0.000 claims description 4
- 239000004700 high-density polyethylene Substances 0.000 claims description 4
- 229920001684 low density polyethylene Polymers 0.000 claims description 4
- 239000004702 low-density polyethylene Substances 0.000 claims description 4
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 4
- 229920000117 poly(dioxanone) Polymers 0.000 claims description 4
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 4
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920008285 Poly(ether ketone) PEK Polymers 0.000 claims description 3
- 230000002051 biphasic effect Effects 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 claims description 3
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 claims description 2
- AMFGWXWBFGVCKG-UHFFFAOYSA-N Panavia opaque Chemical compound C1=CC(OCC(O)COC(=O)C(=C)C)=CC=C1C(C)(C)C1=CC=C(OCC(O)COC(=O)C(C)=C)C=C1 AMFGWXWBFGVCKG-UHFFFAOYSA-N 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 229920010741 Ultra High Molecular Weight Polyethylene (UHMWPE) Polymers 0.000 claims description 2
- 238000013459 approach Methods 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- UQGPCEVQKLOLLM-UHFFFAOYSA-N pentaneperoxoic acid Chemical compound CCCCC(=O)OO UQGPCEVQKLOLLM-UHFFFAOYSA-N 0.000 claims description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
- 229920002492 poly(sulfone) Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920002643 polyglutamic acid Polymers 0.000 claims description 2
- 229920001299 polypropylene fumarate Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 238000009700 powder processing Methods 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 239000007943 implant Substances 0.000 abstract description 40
- 230000000399 orthopedic effect Effects 0.000 abstract description 6
- 239000011159 matrix material Substances 0.000 description 43
- 230000004927 fusion Effects 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 15
- 239000000316 bone substitute Substances 0.000 description 8
- 230000008021 deposition Effects 0.000 description 8
- 229920001652 poly(etherketoneketone) Polymers 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000008468 bone growth Effects 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000007547 defect Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000807 solvent casting Methods 0.000 description 5
- 238000010146 3D printing Methods 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000010100 freeform fabrication Methods 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 238000000110 selective laser sintering Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000001523 electrospinning Methods 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 238000005245 sintering Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002145 thermally induced phase separation Methods 0.000 description 3
- 239000004416 thermosoftening plastic Substances 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 239000007966 viscous suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000009941 weaving Methods 0.000 description 3
- 229910052586 apatite Inorganic materials 0.000 description 2
- 238000000071 blow moulding Methods 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000000515 collagen sponge Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004820 osteoconduction Effects 0.000 description 2
- 230000000278 osteoconductive effect Effects 0.000 description 2
- 230000004819 osteoinduction Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000004382 potting Methods 0.000 description 2
- 238000010107 reaction injection moulding Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- 239000004634 thermosetting polymer Substances 0.000 description 2
- 238000001721 transfer moulding Methods 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
- A61F2/4455—Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
- A61F2/4455—Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages
- A61F2/4465—Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages having a circular or kidney shaped cross-section substantially perpendicular to the axis of the spine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C67/00—Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00
- B29C67/20—Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00 for porous or cellular articles, e.g. of foam plastics, coarse-pored
- B29C67/202—Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00 for porous or cellular articles, e.g. of foam plastics, coarse-pored comprising elimination of a solid or a liquid ingredient
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/0066—Use of inorganic compounding ingredients
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/28—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/36—After-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2/30965—Reinforcing the prosthesis by embedding particles or fibres during moulding or dipping
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2835—Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
- A61F2002/30006—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in density or specific weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
- A61F2002/30011—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in porosity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
- A61F2002/30032—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in absorbability or resorbability, i.e. in absorption or resorption time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30065—Properties of materials and coating materials thermoplastic, i.e. softening or fusing when heated, and hardening and becoming rigid again when cooled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/30199—Three-dimensional shapes
- A61F2002/30224—Three-dimensional shapes cylindrical
- A61F2002/30225—Flat cylinders, i.e. discs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/30199—Three-dimensional shapes
- A61F2002/30224—Three-dimensional shapes cylindrical
- A61F2002/30235—Three-dimensional shapes cylindrical tubular, e.g. sleeves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30621—Features concerning the anatomical functioning or articulation of the prosthetic joint
- A61F2002/30622—Implant for fusing a joint or bone material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2/30771—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves
- A61F2002/30904—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves serrated profile, i.e. saw-toothed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2002/3092—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth having an open-celled or open-pored structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2/30942—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
- A61F2002/30957—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using a positive or a negative model, e.g. moulds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0071—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof thermoplastic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0069—Three-dimensional shapes cylindrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0015—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in density or specific weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0018—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in elasticity, stiffness or compressibility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0023—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in porosity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/003—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time
- A61F2250/0031—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time made from both resorbable and non-resorbable prosthetic parts, e.g. adjacent parts
Definitions
- the present disclosure relates generally to composite biomaterials and more particularly to porous composite biomaterials and related methods.
- Natural bone grafts such as autogenous bone grafts (autografts) are commonly used in procedures for repairing or replacing bone defects because they provide good structural support and osteoinductivity. Natural bone grafts involve removing or harvesting tissue from another part of a host's body (e.g., typically from the iliac crest, hip, ribs, etc.) and implanting the harvested tissue in the defect site. Not only do these grafts require an added surgical procedure needed to harvest the bone tissue, these grafts have limitations, including for example, transplant site morbidity.
- One alternative to autografts is allografts, which involve removing and transplanting tissue from another human (e.g., from bone banks that harvest bone tissue from cadavers) to the defect site.
- DBM Demineralized bone matrix
- Synthetic bone substitute materials have been researched in the treatment of diseased bone (e.g., osteoporosis), injured bone (e.g., fractures), or other bone defects in lieu of natural bone grafts. Synthetic bone substitutes are viable alternatives to the more traditional methods described above. However, synthetic substitute materials used to repair diseased bones and joints should function or perform biologically and mechanically (i.e., as the structural support role of the bone itself) by, for example, mimicking the density and overall physical structure of natural bone to provide a framework for ingrowth of new tissue.
- One type or application of a synthetic bone substitute is a scaffold, which provides support for bone-producing cells.
- Scaffolds may be biodegradable, which degrade in vivo, or they may be non-biodegradable to provide permanent implant fixation (e.g., spinal fusion cages).
- scaffolds are typically biocompatible, and some may be bioactive, bioresorbable, osteoconductive, and/or osteoinductive. The shapability, deliverability, cost, and ability to match the mechanical properties of the surrounding host tissue are other factors that vary among different types of scaffolds and other bone substitutes.
- FIG. 1A is a perspective view of an example porous composite material described herein.
- FIG. 1B is a cross-sectional view of a portion of the example porous composite material of FIG. 1A .
- FIG. 2A-2C are scanning electron micrographs of a portion of the example porous composite material shown in increasing magnification.
- FIGS. 3 is graphical representation of the elastic modulus of example apatite reinforced polymer composites versus the reinforcement volume fraction.
- FIG. 4 shows scanning electron micrograph of a portion of the surface of an example composite material reinforced with calcium phosphate whiskers embedded within and exposed on the surface, and schematically showing the orientation of the whiskers relative to the loading direction of the material or scaffold strut.
- FIG. 5A is a schematic illustration of a known spinal fusion cage inserted between spinal vertebrae.
- FIG. 5B illustrates the example known spinal fusion cage of FIG. 5A .
- FIG. 6 illustrates another example scaffold described herein.
- FIG. 7 illustrates yet another example scaffold described herein.
- FIG. 8 is a flow diagram illustrating an example process of creating an example composite material apparatus described herein.
- the example methods, apparatus, and materials described herein provide a biocompatible, bioactive synthetic porous composite for use as synthetic bone substitute materials.
- the synthetic composite may provide a synthetic porous scaffold for use an orthopedic implant and/or be injectable via percutaneous or surgical injection to cure in vivo. Because the example composite material is used to form a scaffold or matrix that is used in an implantable device, the descriptions of one or more of these structures may also describe one or more of the other structures.
- the synthetic porous composites are tailored to mimic biological and mechanical properties of bone tissue for implant fixation, synthetic bone graft substitutes, tissue engineering scaffolds, interbody spinal fusion, or other orthopedic applications.
- An example porous composite material described herein reduces subsidence and/or bone resorption resulting from mechanical mismatch problems between a synthetic scaffold of an implant device and the peri-implant tissue. Additionally, porosity and/or the pore sizes of the example synthetic composite are tailorable to specific applications to effectively promote the vascularization and growth of bone in the pores and/or void spaces of the example scaffolds, thereby improving bonding between the scaffolds and peri-implant tissue.
- the example composite material or scaffolds are synthesized or made through a process that enables reinforcement particles to be integrally formed with or embedded within polymer matrices.
- the polymer matrices embedded with the reinforcement material provide improved material properties (e.g., stiffness, fatigue strength, and toughness).
- the reinforcement particles are also exposed on a surface of the matrices, which promotes bioactivity and/or bioresorption.
- the process provides flexibility to tailor the level of reinforcement particles and porosity for a desired application.
- a porogen material may be used to vary the porosity, while the pore size is tailored by, for example, sieving the porogen to a desired size.
- the mechanical properties (e.g., stiffness, strength, toughness, etc.) of the example scaffold of the implant device may be tailored to match those of the adjacent peri-implant bone tissue to reduce mechanical mismatch problems. Reducing mechanical mismatch provides a decreased risk of subsidence, stress shielding, bone resorption, and/or subsequent failure of adjacent peri-implant bone tissue. Additionally, the example scaffold of the implant device may include a significantly high porosity to promote bone ingrowth, while exhibiting significantly higher effective mechanical properties such as, for example, the mechanical properties of trabecular bone.
- the example composite material includes a continuous porous biocompatible matrix having a thermoplastic polymer matrix reinforced with anisometric calcium phosphate particles.
- a composite material includes a polyetheretherketone (PEEK) or a polyetherketoneketone (PEKK) matrix reinforced with various volume fractions of hydroxyapatite (HA) whiskers (e.g., 20 or 40 volume percent), wherein the matrix is approximately between 70% and 90% porous.
- PEEK polyetheretherketone
- PEKK polyetherketoneketone
- HA hydroxyapatite
- the porous matrix includes a biocompatible, microporous polymer cage reinforced with anisometric calcium phosphate particles and bone morphogenic protein (BMP) such as, for example, rhBMP-2, which can be dispersed or accommodated by the void spaces and/or pores of the example porous scaffold and/or exposed on the surface of the example porous scaffold. Additionally, the BMP binds to the calcium phosphate further localizing the BMP to the surface of the scaffold or matrix.
- BMP bone morphogenic protein
- the example composite materials described herein may be used for applications such as, for example, synthetic bone graft substitutes, bone ingrowth surfaces applied to existing implants, tissue engineering scaffolds, interbody spinal fusion cages, etc.
- carrier materials e.g., collagen, hydrogels, etc.
- growth factors such as BMP
- a femur includes a cortical bone that has a relative porosity on the order of about 5-15%, and a trabecular bone that has a porosity on the order of about 75-95%. Due to the highly significant porosity differences, the trabecular bone exhibits significantly lower effective mechanical properties compared to the cortical bone. Therefore, depending on the application, synthetic composite materials for use as scaffolds and/or spinal fusion cages or other implant devices should possess the mechanical properties exhibited by the cortical bone or the trabecular bone, but must also have effective porosity to promote bone growth.
- the example scaffold of the implant device described herein may be tailored to substantially match or mimic the mechanical properties (e.g., stiffness, strength, toughness, etc.) of the adjacent and/or substituted bone tissue.
- the mechanical properties e.g., stiffness, strength, toughness, etc.
- Several factors may be varied during the synthesis of the composite material and scaffold of the implant device to tailor the mechanical properties including the calcium phosphate reinforcement volume fraction, aspect ratio, size and orientation; the polymer; and the size, volume fraction, shape and directionality of the void space and/or porosity. Tailoring the mechanical properties of the scaffold reduces the likelihood of mechanical mismatch leading to a decreased risk of subsidence, stress shielding, bone resorption and/or subsequent failure of adjacent vertebrae.
- FIG. 1A illustrates the example synthetic porous composite material 100 described herein.
- FIG. 1B is a cross-sectional view of a portion of the example porous composite material 100 of FIG. 1A .
- the example synthetic composite material 100 provides a synthetic porous scaffold 101 for use or in as an orthopedic implant.
- the example synthetic porous composite material 100 includes a porous thermoplastic polymer (e.g., a PEEK polymer) matrix 102 having anisometric calcium phosphate reinforcement particles 104 integrally formed or embedded with the matrix 102 and/or exposed on a surface of the matrix.
- a porous thermoplastic polymer e.g., a PEEK polymer
- the porous polymer matrix 102 includes a substantially continuous porosity and a plurality of pores 106 to enable bone ingrowth into the porous matrix 102 .
- the matrix 102 is substantially continuously interconnected via a plurality of struts 108 .
- At least one of the plurality of struts 108 may be a load-bearing strut.
- FIGS. 2A-2C are scanning electron micrographs showing increasing magnification of a portion of an example scaffold 200 with struts 202 .
- the example scaffold 200 is a PEEK scaffold reinforced with 40% by volume HA whiskers 204 .
- FIG. 2A illustrates the architecture or matrix 206 of the scaffold 200 and FIG. 2B illustrates an enlarged portion of the struts 202 .
- the HA whiskers 204 are integrally formed and/or embedded within the matrix 206 of the scaffold 200 for reinforcement.
- the HA whiskers 204 are also exposed on a surface 208 of the matrix of the scaffold 200 for bioactivity and/or bioresorption, as noted above.
- the HA whiskers 204 are aligned in a sheet texture and are exposed on the surface 208 of the struts 202 .
- thermoplastic polymer of the example scaffolds described herein may be a biodegradable polymer for synthetic bone graft substitute applications, or nonbiodegradable for implant fixation applications.
- the thermoplastic polymer includes a continuous matrix of a composite material and is biocompatible and/or bioresorbable as described above.
- the polymer may be a radiolucent polymer, bioresorbable (i.e., a material capable of being resorbed by a patient under normal physiological conditions) and/or non-bioresorbable, as desired.
- the thermoplastic polymer matrix may include a polymer suitable for injection via percutaneous or surgical injection so that the composite material 100 cures in vivo.
- Suitable non-resorbable polymers include, without limitation, polyaryletherketone (PAEK), polyetheretherketone (PEEK), polyetherketonekteone (PEKK), polyetherketone (PEK), polyethylene, high density polyethylene (HDPE), ultra-high molecular weight polyethylene (UHMWPE), low density polyethylene (LDPE), polyethylene oxide (PEO), polyurethane, polypropylene, polypropylene oxide (PPO), polysulfone, polypropylene, copolymers thereof, and blends thereof.
- PAEK polyaryletherketone
- PEEK polyetheretherketone
- PEKK polyetherketonekteone
- PEK polyetherketone
- PEK polyethylene, high density polyethylene (HDPE), ultra-high molecular weight polyethylene (UHMWPE), low density polyethylene (LDPE), polyethylene oxide (PEO), polyurethane, polypropylene, polypropylene oxide (PPO), polysulfone, polypropylene, copolymers thereof
- Suitable bioresorbable polymers include, without limitation, poly(DL-lactide) (PDLA), poly(L-lactide) (PLLA), poly(glycolide) (PGA), poly( ⁇ -caprolactone) (PCL), poly(dioxanone) (PDO), poly(glyconate), poly(hydroxybutyrate) (PHB), poly(hydroxyvalerate (PHV), poly(orthoesters), poly(carboxylates), poly(propylene fumarate), poly(phosphates), poly(carbonates), poly(anhydrides), poly(iminocarbonates), poly(phosphazenes), copolymers thereof, and blends thereof.
- PDLA poly(DL-lactide)
- PLLA poly(L-lactide)
- PGA poly(glycolide)
- PCL poly( ⁇ -caprolactone)
- PDO poly(dioxanone)
- PDO poly(glyconate), poly(hydroxybutyrate) (PH
- Suitable polymers that are injectable via percutaneous or surgical injection that cure in vivo include, without limitation, polymethylmethacrylate (PMMA), and other polyacrylics from monomers such as bisphenol a hydroxypropylmethacrylate (bis-GMA) and/or tri(ethylene glycol) dimethacrylate (TEG-DMA).
- PMMA polymethylmethacrylate
- bis-GMA bisphenol a hydroxypropylmethacrylate
- TEG-DMA tri(ethylene glycol) dimethacrylate
- synthetic substitute composite materials made of polymers satisfy the functional criteria of an implantable device because they are, for example, formable and inexpensive, polymers alone lack biological efficacy to promote bone growth and/or may lack requisite mechanical properties to support load levels.
- the polymers are reinforced with calcium phosphates.
- the aspect ratio, size, volume fraction and degree of preferred orientation of the calcium phosphate particles 104 may be tailored for the desired material properties and implant performance. For example, consider the information presented in FIG. 3 , which is a graphical illustration of the elastic modulus of HA whisker and powder reinforced polymer composite materials versus the volume fraction percentage of the apatite calcium phosphates that is mixed with the polymer matrix.
- the shaded areas of FIG. 3 show approximate regions for the given mechanical property of the human cortical bone tissue.
- the elastic modulus of the composite materials increases with increasing HA content.
- increasing the level of HA reinforcement in polymer composites increases cellular activity during osteointegration.
- the calcium phosphate reinforcement particles 104 may be in the form of single crystals or dense polycrystals but are at least in some portion anisometric.
- “Anisometric” refers to any particle morphology (shape) that is not equiaxed (e.g., spherical), such as whiskers, plates, fibers, etc.
- Anisometric particles are usually characterized by an aspect ratio.
- HA single crystals are characterized by the ratio of dimensions in the c- and a-axes of the hexagonal crystal structure.
- the anisometric particles in the present disclosure have an aspect ratio greater than 1.
- the mean aspect ratio of the reinforcement particles is from about 1 to about 100.
- the reinforcement particles can be provided in an amount of from about 1% by volume of the composite biomaterial to about 60% by volume, and for example, from about 20% by volume of the composite to about 50% by volume.
- the calcium phosphate reinforcements particles 104 may be oriented in bulk or near the surface of the polymer matrix 102 to provide directional properties, if desired. For example, if the reinforcement particles 104 are predominately aligned within the matrix 102 the morphological alignment of the particles 104 provides anisotropy for the overall composite 100 , which can be tailored to be similar to the anisotropic mechanical properties of bone tissues.
- FIG. 4 shows a micrograph of anisometric calcium phosphate reinforcement 400 on the surface of a dense composite polymer matrix 402 . Also shown in FIG. 4 is a schematic illustration of a portion of matrix 402 and illustratively showing the orientation of the reinforcement particles 400 relative to the loading direction of the material and/or a scaffold strut, which is, for example, at an angle ⁇ .
- the reinforcement particles 104 may have a maximum dimension from about 20 nm to about 2 mm, and for example, between 20 nm to about 100 ⁇ m. While both nano- and micro-scale calcium phosphate particles improve the mechanical properties of the example synthetic composite material 100 described herein, nano-scale calcium phosphate particles are particularly effective for enhancing bioresorbability and cell attachment, and micro-scale particles are particularly effective for obtaining a uniform dispersion within the matrix 102 .
- Suitable calcium phosphates may include, without limitation, calcium HA, HA whiskers, HA, carbonated calcium HA, beta-tricalcium phosphate (beta-TCP), alpha-tricalcium phosphate (alpha-TCP), amorphous calcium phosphate (ACP), octacalcium phosphate (OCP), tetracalcium phosphate, biphasic calcium phosphate (BCP), anhydrous dicalcium phosphate (DCPA), dicalcium phosphate dihydrate (DCPD), anhydrous monocalcium phosphate (MCPA), monocalcium phosphate monohydrate (MCPM), and combinations thereof.
- DCPA dicalcium phosphate
- DCPD dicalcium phosphate dihydrate
- MCPA monocalcium phosphate monohydrate
- MCPM monocalcium phosphate monohydrate
- a synthetic composite material 100 not only bears physiological levels of load, but also promotes oseteointegration—the direct structural and functional connection between the living bone and the surface of the load-bearing implant.
- the bioactive calcium phosphate particles 104 e.g., HA whiskers
- exposed on the surface of the example porous matrix 102 promote a stable bone-implant interface. Osteointegration also requires the vascularization and growth of bone into an implant via interconnected and/or continuous porosity.
- the size, volume fraction, shape, and directionality of the void spaces and/or pores 106 may be tailored to optimize osteoconduction and implant mechanical properties.
- the pores 106 may be any size or shape, while maintaining a continuous network to promote a fusion through the formation of new bone tissue in the void spaces and/or pores 106 .
- the pores 106 may be present throughout the matrix 102 as illustrated in FIG. 1A .
- the pores 106 may be functionally graded in any material or implant direction, for example, radially, as shown in FIGS. 6 and 7 , from a highly porous region to a relatively dense region or may include a void space.
- the change in porosity from one region to another may be very distinct, for example as shown in FIGS.
- the graded change may be uniform or variant.
- the central void may be any shape or size, and may receive (e.g., be filled) a material, a structure, or the composite material 100 (i.e., the composite material graded from the porous outer surface to a dense center), thereby forming a porous outer perimeter and a dense central region. Examples are further described in connection with FIGS. 6 and 7 below.
- the porosity and/or pore sizes 106 may be selectively formed by the inclusion of, for example, a porogen material during synthesis of the composite material 100 .
- Pores spaces may range from about 100 ⁇ m to about 500 ⁇ m, and, for example, from about 250 ⁇ m to about 500 ⁇ m.
- the example composite biomaterial 100 may additionally contain some fraction of microporosity within scaffold struts that is less than about 10 ⁇ m in size.
- the total amount of porosity within porous regions may range from about 1% to about 90% by volume, and, for example, between about 70% and 90% by volume.
- the porosity may also be tailored via other processes such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, and rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
- processes such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, and rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
- the example composite material 100 may optionally include additives, if desired.
- the composite material 100 may include one or more surface-active agents to enhance interfacial bonding between the reinforcement particles 104 and the polymer matrix 102 .
- the void spaces and/or pores 106 may accommodate and deliver one or more growth factors such as, for example, BMP, to enhance osteoinductivity and/or bone regeneration.
- the void spaces and/or pores 106 may also accommodate and deliver one or more transcription factors, matrix metalloproteinases, peptides, proteins, bone cells, progenitor cells, blood plasma, bone marrow aspirate, or combinations thereof, to improve or speed bone regeneration, or resorption and replacement of the biomaterial.
- the void spaces and/or pores 106 may further accommodate a carrier material that may be incorporated into the void spaces and/or pores 106 .
- the carrier material may include, for example, a collagen sponge, membrane, or a hydrogel material to deliver the growth factor material such as, for example, the BMP.
- FIG. 5A is an illustration showing a known interbody spinal fusion cage 500 .
- the example spinal fusion cage 500 is implanted in the inter-vertebral space 502 between two adjacent vertebrae 506 and 508 .
- a disc 510 due to degeneration, herniation, etc., is typically removed and replaced by the spinal fusion cage 500 .
- the spinal fusion cage 500 is used to support or restore vertebral height, and, thus, stabilize or retain adjacent vertebrae 506 and 508 in a desired position. Additionally, the spinal fusion cage 500 is to promote fusion between the vertebrae 506 and 508 .
- FIG. 5B is an enlarged illustration of the known spinal fusion cage 500 of FIG. 5A .
- a typical spinal fusion cage 500 includes a body 510 having a dense outer region 512 and a void 514 at its center.
- the dense outer surface 512 may be made of PEEK, titanium, or other material that can be used to support the vertebrae 506 and 508 .
- the spinal fusion cage 500 made of a PEEK, titanium, etc. cannot attach to the bone.
- the center void 514 is typically provided with a packing material (not shown) such as, a natural bone graft, a collagen sponge that retains bone growth factors, or the spinal fusion cage 500 is coated with the bone growth factors or other agents that promote osteoinduction.
- the example porous scaffold 101 having the composite material 100 described herein, and with respect to FIG. 1A can be implemented with the spinal fusion cage 500 of FIGS. 5A and 5B to replace the packing materials, such as natural bone graft.
- the porous scaffold 101 promotes bone ingrowth and the pores 106 may accommodate or deliver for example, a BMP, to further improve rate of growth (fusion rate).
- the calcium phosphate e.g., HA whisker
- FIG. 6 illustrates another example scaffold or matrix 600 implemented with the example composite material 100 described herein.
- the example scaffold 600 may be implemented as an interbody spinal fusion cage.
- the scaffold 600 includes a body 602 having a porous polymer matrix 604 integrally formed or embedded with anisometric calcium phosphate particles 606 .
- the matrix 604 of the example scaffold 600 includes a radiolucent polymer (e.g., PEEK) integrally formed or embedded with anisometric calcium phosphate reinforcements 606 such as, for example, HA whiskers.
- the radiolucent polymer provides improved radiographic analysis of fusion following implantation.
- the example scaffold 600 may also include a BMP such as, for example, rhBMP- 2 .
- the example scaffold 600 is a biocompatible, microporous polymer scaffold or matrix supplemented with anisometric calcium phosphate reinforcements and BMP.
- the example scaffold 600 may formed so that the pores are functionally graded in any material or implant direction such as, for example, radially, as shown in FIG. 6 , from a highly porous center or central region 608 to relatively dense outer region or surface 610 .
- the change in porosity from one region to another may be distinct or gradual from the central region 608 to the outer region 610 . Further, the graded change may be uniform or variant.
- the dense outer region 610 provides structural integrity along with the advantages of the composite material 100 described herein.
- the porous structure 604 has pore sizes that range between about 100 ⁇ m and about 500 ⁇ m, and preferably, between about 250 ⁇ m and about 500 ⁇ m, and a porosity that ranges between about 1% to about 90%.
- FIG. 7 illustrates another example scaffold 700 .
- the porous scaffold 700 includes a porous matrix 702 having the composite material 100 described herein.
- the porous scaffold 700 includes a center or central void 704 that may be any shape or size.
- the central void 704 may receive a material 706 , a stem, or any other substance or structure, illustratively depicted by dashed lines.
- the central void 704 may receive a stem 706 (e.g., an implant) such as, for example, a titanium stem, a dense composite stem (e.g., a PEEK composite stem), or any other suitable material or structure.
- a stem 706 e.g., an implant
- a dense composite stem e.g., a PEEK composite stem
- the scaffold 700 is formed so that the pores are functionally graded in any material or implant direction, for example, radially as shown in FIG. 7 , from a high porous outer region or surface 702 to a relatively dense center or central region 708 .
- the change in porosity from one region to another may be distinct or gradual from the central region 708 to the highly porous outer region 702 .
- the graded change may be uniform or variant.
- the example scaffold 700 forms a porous perimeter having a dense core, where the material is continuous from the porous perimeter to the dense core.
- the dense central region 708 provides structural integrity along with the advantages of the composite material 100 described herein.
- the porous matrix 702 and the dense central region 708 may have pore sizes that range between about 100 ⁇ m and about 500 ⁇ m, and preferably, between about 250 ⁇ m and about 500 ⁇ m, and a porosity that ranges between about 1% to about 90%.
- the spinal fusion cage 700 may include a microporosity having pore sizes less than about 10 ⁇ m.
- the composite material 100 and/or the scaffolds 101 , 600 , 700 may also include a roughened surface such as, for example, serrated teeth, that come into direct contact with the adjacent peri-implant tissue to prevent movement relative to the peri-implant tissue after implantation.
- the scaffolds 101 , 600 , 700 may include holes, notches, pins, radiographic markers, or other features that may be gripped or otherwise used for positioning of the scaffolds 101 , 600 , 700 by minimally invasive surgical tools and procedures.
- the example composite material 100 and/or the scaffolds 101 , 600 , 700 may be manufactured by methods common to reinforced thermoplastic and thermosetting polymers, including but not limited to injection molding, reaction injection molding, compression molding, transfer molding, extrusion, blow molding, pultrusion, casting/potting, solvent casting, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, and rapid prototyping processes such as solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
- methods common to reinforced thermoplastic and thermosetting polymers including but not limited to injection molding, reaction injection molding, compression molding, transfer molding, extrusion, blow molding, pultrusion, casting/potting, solvent casting, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally
- FIG. 8 is a flowchart of an example method 800 that may be used to synthesize the example composite material 100 and/or scaffolds 101 , 600 , 700 described herein. While an example manner of synthesizing the example composite material 100 and/or scaffolds 101 , 600 , 700 has been illustrated in FIG. 8 , one or more of the steps and/or processes illustrated in FIG. 8 may be combined, divided, re-arranged, omitted, eliminated and/or implemented in any other way. Further still, the example method of FIG. 8 may include one or more processes and/or steps in addition to, or instead of, those illustrated in FIG. 8 , and/or may include more than one of any or all of the illustrated processes and/or steps. Further, although the example method is described with reference to the flow chart illustrated in FIG. 8 , persons of ordinary skill in the art will readily appreciate that many other methods of synthesizing the example composite material 100 and/or scaffolds 101 , 600 , 700 may alternatively be used.
- the composite material 100 and/or the scaffolds 101 , 600 , 700 are processed using a powder processing approach in conjunction with compression molding and particle leaching techniques and is particularly suited for achieving a high concentration (e.g., >40 vol %) of well-dispersed (and aligned, if desired) anisometric calcium phosphate reinforcements (e.g., HA whiskers) in a thermoplastic matrix (e.g., PEEK) with minimal degradation of the calcium phosphate size/shape during processing.
- a high concentration e.g., >40 vol %
- anisometric calcium phosphate reinforcements e.g., HA whiskers
- a thermoplastic matrix e.g., PEEK
- the calcium phosphate reinforcement volume fraction, aspect ratio, size and orientation; the polymer; and the size, volume fraction, shape and directionality of the void space and/or porosity may be tailored to vary the mechanical properties of the composite material 100 and/or scaffolds 101 , 600 , 700 .
- a polymer such as, for example, PEEK, and anisometric calcium phosphate particles, such as HA whiskers, are provide in powder form (block 802 ).
- the PEEK polymer powder may have, for example, a mean particle size of about 26 ⁇ m.
- the HA whiskers may be synthesized (block 801 ) using, for example, the chelate decomposition method.
- the PEEK powder and the synthesized HA whiskers are co-dispersed in a fluid (block 804 ) such as, for example ethanol, and mixed (block 804 ) using, for example, ultrasonication under constant stirring—forming a viscous suspension.
- a fluid such as, for example ethanol
- the porosity of the mixture is selectively varied and/or tailored (block 806 ).
- the porosity may be formed and tailored by the addition of a suitable porogen material such as, for example, NaCl, wax, polysaccharides (sugars), cellulose, etc.
- the extent of the porosity can be controlled by varying the amount of porogen used (block 805 ), while the pore size could be tailored by sieving the porogen (block 807 ) to a desired size prior to mixing the porogen with the polymer mixture.
- the porosity and/or the pore size of the polymer matrix may be selectively varied using any other suitable methods and/or process(es) such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, or rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
- suitable methods and/or process(es) such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, or rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing
- the viscous suspension is wet-consolidated (block 808 ) by, for example, vacuum filtration and drying to remove any residual fluid (i.e., ethanol).
- the composite mixture is densified (block 810 ) by, for example, uniaxial compression, to form a composite preform.
- the preform is compression molded (block 812 ) and/or sintered at elevated temperatures (e.g., approximately 20° C. to 400° C.) sufficient to fuse the polymer particles with minimal damage to the calcium phosphate reinforcements.
- elevated temperatures e.g., approximately 20° C. to 400° C.
- the process or composite material may be heated to a desired processing temperature and the implant may be shaped or formed (block 814 ). Densifying and molding the composite material includes aligning the calcium phosphate reinforcement particles (e.g., HA whiskers) morphologically and/or crystallographically within the scaffold struts.
- the scaffold may have any shape and/or size (e.g., any polygonal shape) and can be formed by methods common to reinforced thermoplastic and thermosetting polymers, including but not limited to injection molding, reaction injection molding, compression molding, transfer molding, extrusion, blow molding, pultrusion, casting/potting, solvent casting, and rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es).
- the composite material 100 and/or the scaffolds 101 , 600 , 700 are formed by the mold walls and/or machining after molding.
- the composite material undergoes a leaching process (block 816 ) to remove, for example, the porogen used during synthesis of the composite material.
- the leaching may occur, for example, via a dissolution method, heating method, and/or any other suitable methods and/or process(es). More specifically, dissolution may include immersing the scaffold in a fluid, such as, for example, deionized water.
- viscous flow of the polymer/reinforcement mixture during molding can be designed to tailor the preferred orientation of the anisometric reinforcements in the implant.
- surface-active agents may be added during the mixing process and/or to the surface of the composite material to enhance interfacial bonding between reinforcement particles and the matrix.
- HA whiskers were synthesized using the chelate decomposition method. The as-synthesized HA whiskers were measured by optical microscopy to have a mean length of 21.6 ⁇ m, width of ⁇ m and aspect ratio of 7.6.
- composite scaffolds with 75, 82.5 and 90% porosity were processed with 0-40 vol % HA whisker reinforcement.
- Appropriate amounts of polymer powder and HA whiskers were co-dispersed in ethanol via a sonic dismembrator and mechanical stirring at 1200 rpm.
- the appropriate amount of the NaCl i.e., porogen
- the total scaffold volume consisted of the material volume plus the pore volume.
- the reinforcement level was calculated based the desired material volume, while the porosity level was calculated based on the total scaffold volume.
- the viscous suspension was wet-consolidated using vacuum filtration.
- the powder mixture was dried overnight in a forced convection oven at 90° C. and densified at 125 MPa in a cylindrical pellet die using a hydraulic platen press.
- the die and densified powder mixture was heated in a vacuum oven to the desired processing temperature and transferred to a hydraulic platen press for compression molding. Scaffolds with 82.5 and 90% porosity were molded at 350° C., while scaffolds with 75% porosity were molded at 350, 365 and 375° C.
- a pressure of 250 MPa was applied to the die as the polymer solidified.
- the sintered composite pellet was ejected from the die and placed approximately 300 mL deionized water for at least 72 h to dissolve the NaCl crystals. The deionized water was changed daily.
- the as-molded composite scaffolds had a diameter of 1 cm and were machined to a height of 1 cm.
- the table below provides mechanical properties of the example PEKK scaffold reinforced with HA whiskers that was processed using a compression molding/particle leaching method such as, for example, the method 800 of FIG. 8 as implemented in the description above.
- the mechanical properties of HA whisker reinforced PEKK were evaluated in uniaxial compression.
- Tensile properties of the HA whisker reinforced PEKK scaffolds were evaluated prior to scaffold fabrication.
- Scaffolds with 0 vol % HA whisker reinforcement and 75% and 90% porosity exhibited yield strengths of 1.25 MPa and 0.15 MPa, respectively.
- Scaffolds with 40 vol % HA whisker reinforcement and 75%, 82% and 90% porosity exhibited yield strengths of 0.52 MPa, 0.13 MPa and 0.04 MPa, respectively.
- the HA content also affected the modulus and failure strain of the scaffolds.
- a scaffold having 75% porosity and 20 vol % reinforcement HA whisker exhibited modulus of 106.3 MPa, compared to a modulus of 69.5 MPa for scaffolds with 0 vol % HA whisker reinforcement.
- the example methods and apparatus described herein offer synthetic porous composite material that may be used for synthetic bone substitutes for implant fixation, fraction fixation, synthetic bone graft substitutes, interbody spinal fusion, tissue engineering scaffolds, or other applications.
- Many aspects of the of the porous composite material may be tailored to provide specific mechanical, biological, and surgical functions, such as, the polymer composition and molecular orientation, porosity and pore size of the porous matrix, or the HA reinforcement content, morphology, preferred orientation, and size.
Abstract
A composite material for use, for example, as an orthopedic implant, that includes a porous reinforced composite scaffold that includes a polymer, reinforcement particles distributed throughout the polymer, and a substantially continuously interconnected plurality of pores that are distributed throughout the polymer, each of the pores in the plurality of pores defined by voids interconnected by struts, each pore void having a size within a range from about 10 to 500 μm. The porous reinforced composite scaffold has a scaffold volume that includes a material volume defined by the polymer and the reinforcement particles, and a pore volume defined by the plurality of pores. The reinforcement particles are both embedded within the polymer and exposed on the struts within the pore voids. The polymer may be a polyaryletherketone polymer and the reinforcement particles may be anisometric calcium phosphate particles.
Description
- This application is a continuation of and claims priority to U.S. patent application Ser. No. 14/078,614, filed on Nov. 13, 2013, entitled “Porous Composite Biomaterials and Related Methods,” now patented, which is a continuation of U.S. patent application Ser. No. 12/039,666, filed on Feb. 28, 2008, entitled “Porous Composite Biomaterials and Related Methods,” which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/904,098, filed on Feb. 28, 2007, entitled “Reinforced Porous Polymer Scaffolds,” and U.S. Provisional Patent Application Ser. No. 60/939,256, filed on May 21, 2007, entitled “Interbody Spinal Fusion Cages Containing Anisometric Calcium Phosphate Reinforcements and Related Methods,” each of which is incorporated herein by reference in its entirety.
- The present disclosure relates generally to composite biomaterials and more particularly to porous composite biomaterials and related methods.
- Natural bone grafts such as autogenous bone grafts (autografts) are commonly used in procedures for repairing or replacing bone defects because they provide good structural support and osteoinductivity. Natural bone grafts involve removing or harvesting tissue from another part of a host's body (e.g., typically from the iliac crest, hip, ribs, etc.) and implanting the harvested tissue in the defect site. Not only do these grafts require an added surgical procedure needed to harvest the bone tissue, these grafts have limitations, including for example, transplant site morbidity. One alternative to autografts is allografts, which involve removing and transplanting tissue from another human (e.g., from bone banks that harvest bone tissue from cadavers) to the defect site. However, allografts are known to induce infection and immunotoxicity, suffer from limited supply and variability, and have a lessened effectiveness because the cells and proteins that promote bone growth are lost during the harvesting process (e.g., during cleansing and disinfecting process). Demineralized bone matrix (DBM) is typically used to induce bone growth at defect sites, but DBM lacks the mechanical properties (e.g., stiffness, strength, toughness, etc.) necessary to be considered a viable option for load-bearing applications.
- Synthetic bone substitute materials have been researched in the treatment of diseased bone (e.g., osteoporosis), injured bone (e.g., fractures), or other bone defects in lieu of natural bone grafts. Synthetic bone substitutes are viable alternatives to the more traditional methods described above. However, synthetic substitute materials used to repair diseased bones and joints should function or perform biologically and mechanically (i.e., as the structural support role of the bone itself) by, for example, mimicking the density and overall physical structure of natural bone to provide a framework for ingrowth of new tissue. One type or application of a synthetic bone substitute is a scaffold, which provides support for bone-producing cells. Scaffolds may be biodegradable, which degrade in vivo, or they may be non-biodegradable to provide permanent implant fixation (e.g., spinal fusion cages). In addition, scaffolds are typically biocompatible, and some may be bioactive, bioresorbable, osteoconductive, and/or osteoinductive. The shapability, deliverability, cost, and ability to match the mechanical properties of the surrounding host tissue are other factors that vary among different types of scaffolds and other bone substitutes.
- Problems may arise when there is a mechanical mismatch between the bone substitute and the surrounding tissue. For example, metallic implants and dense ceramics have mechanical properties that are typically an order of magnitude greater than the bone tissue. As a result, a stiff metal bone substitute implant acts to “shield” the adjacent bone tissue from mechanical stresses, resulting in a weakened bone at the bone-implant interface. Furthermore, efforts to utilize porous ceramics or polymer bone cement in place of stiffer materials have been limited. For example, ceramics possess low fracture toughness, thereby making the orthopedic implant brittle (i.e., susceptible to fracture). Polymers are limited by higher compliance and lower strength, thereby limiting their ability to support physiological load levels. Additionally, conventional orthopedic implant biomaterials are not osteoconductive and bioactive, resulting in a lack of bonding between the implant and the peri-implant tissue.
-
FIG. 1A is a perspective view of an example porous composite material described herein. -
FIG. 1B is a cross-sectional view of a portion of the example porous composite material ofFIG. 1A . -
FIG. 2A-2C are scanning electron micrographs of a portion of the example porous composite material shown in increasing magnification. -
FIGS. 3 is graphical representation of the elastic modulus of example apatite reinforced polymer composites versus the reinforcement volume fraction. -
FIG. 4 shows scanning electron micrograph of a portion of the surface of an example composite material reinforced with calcium phosphate whiskers embedded within and exposed on the surface, and schematically showing the orientation of the whiskers relative to the loading direction of the material or scaffold strut. -
FIG. 5A is a schematic illustration of a known spinal fusion cage inserted between spinal vertebrae. -
FIG. 5B illustrates the example known spinal fusion cage ofFIG. 5A . -
FIG. 6 illustrates another example scaffold described herein. -
FIG. 7 illustrates yet another example scaffold described herein. -
FIG. 8 is a flow diagram illustrating an example process of creating an example composite material apparatus described herein. - In general, the example methods, apparatus, and materials described herein provide a biocompatible, bioactive synthetic porous composite for use as synthetic bone substitute materials. The synthetic composite may provide a synthetic porous scaffold for use an orthopedic implant and/or be injectable via percutaneous or surgical injection to cure in vivo. Because the example composite material is used to form a scaffold or matrix that is used in an implantable device, the descriptions of one or more of these structures may also describe one or more of the other structures. The synthetic porous composites are tailored to mimic biological and mechanical properties of bone tissue for implant fixation, synthetic bone graft substitutes, tissue engineering scaffolds, interbody spinal fusion, or other orthopedic applications. An example porous composite material described herein reduces subsidence and/or bone resorption resulting from mechanical mismatch problems between a synthetic scaffold of an implant device and the peri-implant tissue. Additionally, porosity and/or the pore sizes of the example synthetic composite are tailorable to specific applications to effectively promote the vascularization and growth of bone in the pores and/or void spaces of the example scaffolds, thereby improving bonding between the scaffolds and peri-implant tissue.
- The example composite material or scaffolds are synthesized or made through a process that enables reinforcement particles to be integrally formed with or embedded within polymer matrices. In this manner, the polymer matrices embedded with the reinforcement material provide improved material properties (e.g., stiffness, fatigue strength, and toughness). The reinforcement particles are also exposed on a surface of the matrices, which promotes bioactivity and/or bioresorption. Additionally, the process provides flexibility to tailor the level of reinforcement particles and porosity for a desired application. For example, a porogen material may be used to vary the porosity, while the pore size is tailored by, for example, sieving the porogen to a desired size.
- By varying the volume of the reinforcement particles and the porosity of the example scaffold, the mechanical properties (e.g., stiffness, strength, toughness, etc.) of the example scaffold of the implant device may be tailored to match those of the adjacent peri-implant bone tissue to reduce mechanical mismatch problems. Reducing mechanical mismatch provides a decreased risk of subsidence, stress shielding, bone resorption, and/or subsequent failure of adjacent peri-implant bone tissue. Additionally, the example scaffold of the implant device may include a significantly high porosity to promote bone ingrowth, while exhibiting significantly higher effective mechanical properties such as, for example, the mechanical properties of trabecular bone.
- In particular, the example composite material includes a continuous porous biocompatible matrix having a thermoplastic polymer matrix reinforced with anisometric calcium phosphate particles. More specifically, in one example, a composite material includes a polyetheretherketone (PEEK) or a polyetherketoneketone (PEKK) matrix reinforced with various volume fractions of hydroxyapatite (HA) whiskers (e.g., 20 or 40 volume percent), wherein the matrix is approximately between 70% and 90% porous. In another example, the porous matrix includes a biocompatible, microporous polymer cage reinforced with anisometric calcium phosphate particles and bone morphogenic protein (BMP) such as, for example, rhBMP-2, which can be dispersed or accommodated by the void spaces and/or pores of the example porous scaffold and/or exposed on the surface of the example porous scaffold. Additionally, the BMP binds to the calcium phosphate further localizing the BMP to the surface of the scaffold or matrix.
- The example composite materials described herein may be used for applications such as, for example, synthetic bone graft substitutes, bone ingrowth surfaces applied to existing implants, tissue engineering scaffolds, interbody spinal fusion cages, etc. In each of the applications, carrier materials (e.g., collagen, hydrogels, etc.) containing growth factors, such as BMP, may be incorporated into the pore space of the scaffold of the implant device to further enhance osteoinduction and/or osteoconduction to promote osteointegration.
- Human bone tissues exhibit substantial variation in mechanical properties depending on the tissue density and microstructure. The properties are highly dependent on anatomic location and apparent density of the measured specimen. For example, a femur includes a cortical bone that has a relative porosity on the order of about 5-15%, and a trabecular bone that has a porosity on the order of about 75-95%. Due to the highly significant porosity differences, the trabecular bone exhibits significantly lower effective mechanical properties compared to the cortical bone. Therefore, depending on the application, synthetic composite materials for use as scaffolds and/or spinal fusion cages or other implant devices should possess the mechanical properties exhibited by the cortical bone or the trabecular bone, but must also have effective porosity to promote bone growth.
- To avoid the mechanical mismatch problems, such as stress shielding, the example scaffold of the implant device described herein may be tailored to substantially match or mimic the mechanical properties (e.g., stiffness, strength, toughness, etc.) of the adjacent and/or substituted bone tissue. Several factors may be varied during the synthesis of the composite material and scaffold of the implant device to tailor the mechanical properties including the calcium phosphate reinforcement volume fraction, aspect ratio, size and orientation; the polymer; and the size, volume fraction, shape and directionality of the void space and/or porosity. Tailoring the mechanical properties of the scaffold reduces the likelihood of mechanical mismatch leading to a decreased risk of subsidence, stress shielding, bone resorption and/or subsequent failure of adjacent vertebrae.
-
FIG. 1A illustrates the example synthetic porouscomposite material 100 described herein.FIG. 1B is a cross-sectional view of a portion of the example porouscomposite material 100 ofFIG. 1A . The example syntheticcomposite material 100 provides a syntheticporous scaffold 101 for use or in as an orthopedic implant. - The example synthetic porous
composite material 100 includes a porous thermoplastic polymer (e.g., a PEEK polymer)matrix 102 having anisometric calciumphosphate reinforcement particles 104 integrally formed or embedded with thematrix 102 and/or exposed on a surface of the matrix. In this manner, thepolymer matrix 102 embedded with thereinforcement particles 104 provides high material strength, and thereinforcement particles 104 exposed on the surface of thematrix 102 promote bioactivity and/or bioresorption. Theporous polymer matrix 102 includes a substantially continuous porosity and a plurality ofpores 106 to enable bone ingrowth into theporous matrix 102. In addition, thematrix 102 is substantially continuously interconnected via a plurality ofstruts 108. - Furthermore, at least one of the plurality of
struts 108 may be a load-bearing strut. -
FIGS. 2A-2C are scanning electron micrographs showing increasing magnification of a portion of anexample scaffold 200 withstruts 202. Theexample scaffold 200 is a PEEK scaffold reinforced with 40% by volume HA whiskers 204.FIG. 2A illustrates the architecture ormatrix 206 of thescaffold 200 andFIG. 2B illustrates an enlarged portion of thestruts 202. In the illustrated example, theHA whiskers 204 are integrally formed and/or embedded within thematrix 206 of thescaffold 200 for reinforcement. The HA whiskers 204 are also exposed on asurface 208 of the matrix of thescaffold 200 for bioactivity and/or bioresorption, as noted above. As shown inFIG. 2C , theHA whiskers 204 are aligned in a sheet texture and are exposed on thesurface 208 of thestruts 202. - The thermoplastic polymer of the example scaffolds described herein may be a biodegradable polymer for synthetic bone graft substitute applications, or nonbiodegradable for implant fixation applications. The thermoplastic polymer includes a continuous matrix of a composite material and is biocompatible and/or bioresorbable as described above.
- Additionally, or alternatively, the polymer may be a radiolucent polymer, bioresorbable (i.e., a material capable of being resorbed by a patient under normal physiological conditions) and/or non-bioresorbable, as desired. Further, the thermoplastic polymer matrix may include a polymer suitable for injection via percutaneous or surgical injection so that the
composite material 100 cures in vivo. - Suitable non-resorbable polymers include, without limitation, polyaryletherketone (PAEK), polyetheretherketone (PEEK), polyetherketonekteone (PEKK), polyetherketone (PEK), polyethylene, high density polyethylene (HDPE), ultra-high molecular weight polyethylene (UHMWPE), low density polyethylene (LDPE), polyethylene oxide (PEO), polyurethane, polypropylene, polypropylene oxide (PPO), polysulfone, polypropylene, copolymers thereof, and blends thereof. Suitable bioresorbable polymers include, without limitation, poly(DL-lactide) (PDLA), poly(L-lactide) (PLLA), poly(glycolide) (PGA), poly(□-caprolactone) (PCL), poly(dioxanone) (PDO), poly(glyconate), poly(hydroxybutyrate) (PHB), poly(hydroxyvalerate (PHV), poly(orthoesters), poly(carboxylates), poly(propylene fumarate), poly(phosphates), poly(carbonates), poly(anhydrides), poly(iminocarbonates), poly(phosphazenes), copolymers thereof, and blends thereof. Suitable polymers that are injectable via percutaneous or surgical injection that cure in vivo include, without limitation, polymethylmethacrylate (PMMA), and other polyacrylics from monomers such as bisphenol a hydroxypropylmethacrylate (bis-GMA) and/or tri(ethylene glycol) dimethacrylate (TEG-DMA).
- Although synthetic substitute composite materials made of polymers satisfy the functional criteria of an implantable device because they are, for example, formable and inexpensive, polymers alone lack biological efficacy to promote bone growth and/or may lack requisite mechanical properties to support load levels. To increase the mechanical properties of the polymers, the polymers are reinforced with calcium phosphates. The aspect ratio, size, volume fraction and degree of preferred orientation of the calcium phosphate particles 104 (e.g., HA whisker particles) may be tailored for the desired material properties and implant performance. For example, consider the information presented in
FIG. 3 , which is a graphical illustration of the elastic modulus of HA whisker and powder reinforced polymer composite materials versus the volume fraction percentage of the apatite calcium phosphates that is mixed with the polymer matrix. The shaded areas ofFIG. 3 show approximate regions for the given mechanical property of the human cortical bone tissue. As depicted in the graph, the elastic modulus of the composite materials increases with increasing HA content. In addition, increasing the level of HA reinforcement in polymer composites increases cellular activity during osteointegration. - The calcium
phosphate reinforcement particles 104 may be in the form of single crystals or dense polycrystals but are at least in some portion anisometric. “Anisometric” refers to any particle morphology (shape) that is not equiaxed (e.g., spherical), such as whiskers, plates, fibers, etc. Anisometric particles are usually characterized by an aspect ratio. For example, HA single crystals are characterized by the ratio of dimensions in the c- and a-axes of the hexagonal crystal structure. Thus, the anisometric particles in the present disclosure have an aspect ratio greater than 1. In one example, the mean aspect ratio of the reinforcement particles is from about 1 to about 100. By further example, the reinforcement particles can be provided in an amount of from about 1% by volume of the composite biomaterial to about 60% by volume, and for example, from about 20% by volume of the composite to about 50% by volume. - Due to their morphology, the calcium
phosphate reinforcements particles 104 may be oriented in bulk or near the surface of thepolymer matrix 102 to provide directional properties, if desired. For example, if thereinforcement particles 104 are predominately aligned within thematrix 102 the morphological alignment of theparticles 104 provides anisotropy for theoverall composite 100, which can be tailored to be similar to the anisotropic mechanical properties of bone tissues. For example,FIG. 4 shows a micrograph of anisometriccalcium phosphate reinforcement 400 on the surface of a densecomposite polymer matrix 402. Also shown inFIG. 4 is a schematic illustration of a portion ofmatrix 402 and illustratively showing the orientation of thereinforcement particles 400 relative to the loading direction of the material and/or a scaffold strut, which is, for example, at an angle θ. - Furthermore, there are no limits on the size or amount of the
calcium phosphate particles 104 inmatrix 102, provided that thecalcium phosphate particles 104 are dispersed within and/or exposed at the surface of thepolymer matrix 102. For example, thereinforcement particles 104 may have a maximum dimension from about 20 nm to about 2 mm, and for example, between 20 nm to about 100 μm. While both nano- and micro-scale calcium phosphate particles improve the mechanical properties of the example syntheticcomposite material 100 described herein, nano-scale calcium phosphate particles are particularly effective for enhancing bioresorbability and cell attachment, and micro-scale particles are particularly effective for obtaining a uniform dispersion within thematrix 102. - Suitable calcium phosphates may include, without limitation, calcium HA, HA whiskers, HA, carbonated calcium HA, beta-tricalcium phosphate (beta-TCP), alpha-tricalcium phosphate (alpha-TCP), amorphous calcium phosphate (ACP), octacalcium phosphate (OCP), tetracalcium phosphate, biphasic calcium phosphate (BCP), anhydrous dicalcium phosphate (DCPA), dicalcium phosphate dihydrate (DCPD), anhydrous monocalcium phosphate (MCPA), monocalcium phosphate monohydrate (MCPM), and combinations thereof.
- As described above, a synthetic
composite material 100 not only bears physiological levels of load, but also promotes oseteointegration—the direct structural and functional connection between the living bone and the surface of the load-bearing implant. The bioactive calcium phosphate particles 104 (e.g., HA whiskers) exposed on the surface of the exampleporous matrix 102 promote a stable bone-implant interface. Osteointegration also requires the vascularization and growth of bone into an implant via interconnected and/or continuous porosity. - Thus, the size, volume fraction, shape, and directionality of the void spaces and/or
pores 106 may be tailored to optimize osteoconduction and implant mechanical properties. Thepores 106 may be any size or shape, while maintaining a continuous network to promote a fusion through the formation of new bone tissue in the void spaces and/or pores 106. For example, thepores 106 may be present throughout thematrix 102 as illustrated inFIG. 1A . Also, thepores 106 may be functionally graded in any material or implant direction, for example, radially, as shown inFIGS. 6 and 7 , from a highly porous region to a relatively dense region or may include a void space. The change in porosity from one region to another may be very distinct, for example as shown inFIGS. 6 and 7 , or gradual. Furthermore, the graded change may be uniform or variant. In addition, instead of a graded change there may be a combination of materials having two or more densities of pores. The central void may be any shape or size, and may receive (e.g., be filled) a material, a structure, or the composite material 100 (i.e., the composite material graded from the porous outer surface to a dense center), thereby forming a porous outer perimeter and a dense central region. Examples are further described in connection withFIGS. 6 and 7 below. - As discussed in greater detail below, the porosity and/or pore
sizes 106 may be selectively formed by the inclusion of, for example, a porogen material during synthesis of thecomposite material 100. Pores spaces may range from about 100 μm to about 500 μm, and, for example, from about 250 μm to about 500 μm. The examplecomposite biomaterial 100 may additionally contain some fraction of microporosity within scaffold struts that is less than about 10 μm in size. The total amount of porosity within porous regions may range from about 1% to about 90% by volume, and, for example, between about 70% and 90% by volume. However, the porosity may also be tailored via other processes such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, and rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof. - Additionally, the example
composite material 100 may optionally include additives, if desired. For example, thecomposite material 100 may include one or more surface-active agents to enhance interfacial bonding between thereinforcement particles 104 and thepolymer matrix 102. The void spaces and/orpores 106 may accommodate and deliver one or more growth factors such as, for example, BMP, to enhance osteoinductivity and/or bone regeneration. Furthermore, the void spaces and/orpores 106 may also accommodate and deliver one or more transcription factors, matrix metalloproteinases, peptides, proteins, bone cells, progenitor cells, blood plasma, bone marrow aspirate, or combinations thereof, to improve or speed bone regeneration, or resorption and replacement of the biomaterial. In some examples, the void spaces and/orpores 106 may further accommodate a carrier material that may be incorporated into the void spaces and/or pores 106. The carrier material may include, for example, a collagen sponge, membrane, or a hydrogel material to deliver the growth factor material such as, for example, the BMP. Thecalcium phosphate reinforcements 104 exposed on the surface of theporous matrix 102, along with the porosity, improves the retention of the BMP within thematrix 102 and at the peri-implant interface. -
FIG. 5A is an illustration showing a known interbodyspinal fusion cage 500. The examplespinal fusion cage 500 is implanted in theinter-vertebral space 502 between twoadjacent vertebrae disc 510, due to degeneration, herniation, etc., is typically removed and replaced by thespinal fusion cage 500. Thespinal fusion cage 500 is used to support or restore vertebral height, and, thus, stabilize or retainadjacent vertebrae spinal fusion cage 500 is to promote fusion between thevertebrae -
FIG. 5B is an enlarged illustration of the knownspinal fusion cage 500 ofFIG. 5A . A typicalspinal fusion cage 500 includes abody 510 having a denseouter region 512 and a void 514 at its center. The denseouter surface 512 may be made of PEEK, titanium, or other material that can be used to support thevertebrae spinal fusion cage 500 made of a PEEK, titanium, etc., cannot attach to the bone. Thus, to promote bone ingrowth, thecenter void 514 is typically provided with a packing material (not shown) such as, a natural bone graft, a collagen sponge that retains bone growth factors, or thespinal fusion cage 500 is coated with the bone growth factors or other agents that promote osteoinduction. - The example
porous scaffold 101 having thecomposite material 100 described herein, and with respect toFIG. 1A , can be implemented with thespinal fusion cage 500 ofFIGS. 5A and 5B to replace the packing materials, such as natural bone graft. As noted above, theporous scaffold 101 promotes bone ingrowth and thepores 106 may accommodate or deliver for example, a BMP, to further improve rate of growth (fusion rate). Furthermore, the calcium phosphate (e.g., HA whisker) binds to thebody 510 and localizes the BMP within thecentral void 514, which further promotes osteointegration. -
FIG. 6 illustrates another example scaffold ormatrix 600 implemented with the examplecomposite material 100 described herein. Theexample scaffold 600 may be implemented as an interbody spinal fusion cage. Thescaffold 600 includes abody 602 having aporous polymer matrix 604 integrally formed or embedded with anisometriccalcium phosphate particles 606. Furthermore, thematrix 604 of theexample scaffold 600 includes a radiolucent polymer (e.g., PEEK) integrally formed or embedded with anisometriccalcium phosphate reinforcements 606 such as, for example, HA whiskers. The radiolucent polymer provides improved radiographic analysis of fusion following implantation. Theexample scaffold 600 may also include a BMP such as, for example, rhBMP-2. In another example, theexample scaffold 600 is a biocompatible, microporous polymer scaffold or matrix supplemented with anisometric calcium phosphate reinforcements and BMP. - Additionally, the
example scaffold 600 may formed so that the pores are functionally graded in any material or implant direction such as, for example, radially, as shown inFIG. 6 , from a highly porous center orcentral region 608 to relatively dense outer region orsurface 610. The change in porosity from one region to another may be distinct or gradual from thecentral region 608 to theouter region 610. Further, the graded change may be uniform or variant. The denseouter region 610 provides structural integrity along with the advantages of thecomposite material 100 described herein. In the illustrated example, theporous structure 604 has pore sizes that range between about 100 μm and about 500 μm, and preferably, between about 250 μm and about 500 μm, and a porosity that ranges between about 1% to about 90%. Furthermore, the spinalfusion cage material 600 may include microporosity having pore sizes less than about 10 μm.FIG. 7 illustrates anotherexample scaffold 700. Theporous scaffold 700 includes aporous matrix 702 having thecomposite material 100 described herein. Theporous scaffold 700 includes a center orcentral void 704 that may be any shape or size. Additionally, or alternatively, thecentral void 704 may receive amaterial 706, a stem, or any other substance or structure, illustratively depicted by dashed lines. For example, thecentral void 704 may receive a stem 706 (e.g., an implant) such as, for example, a titanium stem, a dense composite stem (e.g., a PEEK composite stem), or any other suitable material or structure. - Additionally, in other examples, the
scaffold 700 is formed so that the pores are functionally graded in any material or implant direction, for example, radially as shown inFIG. 7 , from a high porous outer region orsurface 702 to a relatively dense center orcentral region 708. The change in porosity from one region to another may be distinct or gradual from thecentral region 708 to the highly porousouter region 702. Further, the graded change may be uniform or variant. In this manner, theexample scaffold 700 forms a porous perimeter having a dense core, where the material is continuous from the porous perimeter to the dense core. The densecentral region 708 provides structural integrity along with the advantages of thecomposite material 100 described herein. In the illustrated example, theporous matrix 702 and the densecentral region 708 may have pore sizes that range between about 100 μm and about 500 μm, and preferably, between about 250 μm and about 500 μm, and a porosity that ranges between about 1% to about 90%. Furthermore, thespinal fusion cage 700 may include a microporosity having pore sizes less than about 10 μm. - In other examples, the
composite material 100 and/or thescaffolds scaffolds scaffolds - The example
composite material 100 and/or thescaffolds -
FIG. 8 is a flowchart of anexample method 800 that may be used to synthesize the examplecomposite material 100 and/orscaffolds composite material 100 and/orscaffolds FIG. 8 , one or more of the steps and/or processes illustrated inFIG. 8 may be combined, divided, re-arranged, omitted, eliminated and/or implemented in any other way. Further still, the example method ofFIG. 8 may include one or more processes and/or steps in addition to, or instead of, those illustrated inFIG. 8 , and/or may include more than one of any or all of the illustrated processes and/or steps. Further, although the example method is described with reference to the flow chart illustrated inFIG. 8 , persons of ordinary skill in the art will readily appreciate that many other methods of synthesizing the examplecomposite material 100 and/orscaffolds - The
composite material 100 and/or thescaffolds composite material 100 and/orscaffolds - A polymer such as, for example, PEEK, and anisometric calcium phosphate particles, such as HA whiskers, are provide in powder form (block 802). The PEEK polymer powder may have, for example, a mean particle size of about 26 μm. The HA whiskers may be synthesized (block 801) using, for example, the chelate decomposition method.
- The PEEK powder and the synthesized HA whiskers are co-dispersed in a fluid (block 804) such as, for example ethanol, and mixed (block 804) using, for example, ultrasonication under constant stirring—forming a viscous suspension.
- After the polymer powder and the HA whiskers are mixed, the porosity of the mixture is selectively varied and/or tailored (block 806). In one example, the porosity may be formed and tailored by the addition of a suitable porogen material such as, for example, NaCl, wax, polysaccharides (sugars), cellulose, etc. The extent of the porosity can be controlled by varying the amount of porogen used (block 805), while the pore size could be tailored by sieving the porogen (block 807) to a desired size prior to mixing the porogen with the polymer mixture. In another examples, the porosity and/or the pore size of the polymer matrix may be selectively varied using any other suitable methods and/or process(es) such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, or rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
- The viscous suspension is wet-consolidated (block 808) by, for example, vacuum filtration and drying to remove any residual fluid (i.e., ethanol). The composite mixture is densified (block 810) by, for example, uniaxial compression, to form a composite preform.
- Following the initial densification, the preform is compression molded (block 812) and/or sintered at elevated temperatures (e.g., approximately 20° C. to 400° C.) sufficient to fuse the polymer particles with minimal damage to the calcium phosphate reinforcements. The process or composite material may be heated to a desired processing temperature and the implant may be shaped or formed (block 814). Densifying and molding the composite material includes aligning the calcium phosphate reinforcement particles (e.g., HA whiskers) morphologically and/or crystallographically within the scaffold struts.
- The scaffold may have any shape and/or size (e.g., any polygonal shape) and can be formed by methods common to reinforced thermoplastic and thermosetting polymers, including but not limited to injection molding, reaction injection molding, compression molding, transfer molding, extrusion, blow molding, pultrusion, casting/potting, solvent casting, and rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es). The
composite material 100 and/or thescaffolds - The composite material undergoes a leaching process (block 816) to remove, for example, the porogen used during synthesis of the composite material. The leaching may occur, for example, via a dissolution method, heating method, and/or any other suitable methods and/or process(es). More specifically, dissolution may include immersing the scaffold in a fluid, such as, for example, deionized water.
- Furthermore, viscous flow of the polymer/reinforcement mixture during molding can be designed to tailor the preferred orientation of the anisometric reinforcements in the implant. Additionally, surface-active agents may be added during the mixing process and/or to the surface of the composite material to enhance interfacial bonding between reinforcement particles and the matrix.
- The following example is provided to further illustrate the example apparatus and methods described herein and, of course, should not be construed as in any way limiting in scope. It is to be understood by one of ordinary skill in the art that the following examples are neither comprehensive nor exhaustive of the many types of methods and apparatus which may be prepared in accordance with the present disclosure.
- In the example, commercially available PEKK and sodium chloride (NaCl) powders with mean particle sizes of 70 and 250 μm, respectively, were used as-received. HA whiskers were synthesized using the chelate decomposition method. The as-synthesized HA whiskers were measured by optical microscopy to have a mean length of 21.6 μm, width of μm and aspect ratio of 7.6.
- In the example, composite scaffolds with 75, 82.5 and 90% porosity were processed with 0-40 vol % HA whisker reinforcement. Appropriate amounts of polymer powder and HA whiskers were co-dispersed in ethanol via a sonic dismembrator and mechanical stirring at 1200 rpm. Following dispersion, the appropriate amount of the NaCl (i.e., porogen) was added to the suspension and mixed by hand using a Teflon coated spatula. The total scaffold volume consisted of the material volume plus the pore volume. Thus, the reinforcement level was calculated based the desired material volume, while the porosity level was calculated based on the total scaffold volume. After mixing, the viscous suspension was wet-consolidated using vacuum filtration. The powder mixture was dried overnight in a forced convection oven at 90° C. and densified at 125 MPa in a cylindrical pellet die using a hydraulic platen press. The die and densified powder mixture was heated in a vacuum oven to the desired processing temperature and transferred to a hydraulic platen press for compression molding. Scaffolds with 82.5 and 90% porosity were molded at 350° C., while scaffolds with 75% porosity were molded at 350, 365 and 375° C. A pressure of 250 MPa was applied to the die as the polymer solidified. After cooling to room temperature, the sintered composite pellet was ejected from the die and placed approximately 300 mL deionized water for at least 72 h to dissolve the NaCl crystals. The deionized water was changed daily. The as-molded composite scaffolds had a diameter of 1 cm and were machined to a height of 1 cm.
- In the example, un-confined compression tests were performed to investigate the mechanical properties of the composite scaffolds. Specimens were tested on an electromagnetic test instrument in phosphate buffered saline (PBS) at 37° C. using a crosshead speed of 1 mm/min. Force-displacement data was used to calculate the elastic modulus, compressive yield stress (CYS), and failure strain of the composite scaffolds. One-way analysis of variance (ANOVA) was used to compare mechanical properties between experimental groups. The compressive properties of HA whisker reinforced PEKK scaffolds were tabulated in table 1.
- The table below provides mechanical properties of the example PEKK scaffold reinforced with HA whiskers that was processed using a compression molding/particle leaching method such as, for example, the
method 800 ofFIG. 8 as implemented in the description above. The mechanical properties of HA whisker reinforced PEKK were evaluated in uniaxial compression. Tensile properties of the HA whisker reinforced PEKK scaffolds were evaluated prior to scaffold fabrication. -
TABLE 1 Molding HA Temper- Elastic Yield Porosity Content ature Modulus CYS Strain (%) (Vol %) (° C.) (MPa) (MPa) (%) 75 0 350 69.5 (12.2) 1.25 (0.16) 5.7 (0.4) 75 0 365 100.7 (10.7) 2.04 (0.26) 4.4 (1.2) 75 0 375 95.6 (10.5) 2.55 (0.34) 4.4 (1.1) 75 20 350 106.3 (15.0) 1.28 (0.13) 3.7 (1.1) 75 20 365 115.4 (13.4) 1.77 (0.30) 2.9 (0.6) 75 20 375 141.1 (39.2) 2.28 (0.35) 2.9 (0.7) 75 40 350 54.0 (18.3) 0.52 (0.17) 2.2 (0.3) 75 40 365 84.3 (41.5) 1.15 (0.38) 2.7 (0.5) 75 40 375 120.2 (29.8) 1.65 (0.34) 2.3 (1.9) 82 40 350 15.7 (6.7) 0.13 (0.03) 2.6 (1.9) 90 0 350 0.75 (0.18) 0.15 (0.04) 30 (0.0) 90 40 350 0.23 (0.13) 0.04 (0.01) 30 (0.0) - As shown in the table, for a given reinforcement level, the compressive modulus decreased with increased porosity, and the yield strength decreased with increased porosity. Scaffolds with 0% vol % HA whisker reinforcement and 75% and 90% porosity exhibited moduli of 69.5 and 0.75 MPa, while scaffolds with 40 vol % HA whisker reinforcement and 75%, 82% and 90% porosity exhibited moduli of 54.0, 15.7 and 0.23 MPa, respectively.
- Scaffolds with 0 vol % HA whisker reinforcement and 75% and 90% porosity exhibited yield strengths of 1.25 MPa and 0.15 MPa, respectively. Scaffolds with 40 vol % HA whisker reinforcement and 75%, 82% and 90% porosity exhibited yield strengths of 0.52 MPa, 0.13 MPa and 0.04 MPa, respectively. The HA content also affected the modulus and failure strain of the scaffolds. A scaffold having 75% porosity and 20 vol % reinforcement HA whisker exhibited modulus of 106.3 MPa, compared to a modulus of 69.5 MPa for scaffolds with 0 vol % HA whisker reinforcement.
- The example methods and apparatus described herein offer synthetic porous composite material that may be used for synthetic bone substitutes for implant fixation, fraction fixation, synthetic bone graft substitutes, interbody spinal fusion, tissue engineering scaffolds, or other applications. Many aspects of the of the porous composite material may be tailored to provide specific mechanical, biological, and surgical functions, such as, the polymer composition and molecular orientation, porosity and pore size of the porous matrix, or the HA reinforcement content, morphology, preferred orientation, and size.
- Although the teachings of the present disclosure have been illustrated in connection with certain examples, there is no intent to limit the present disclosure to such examples. On the contrary, the intention of this application is to cover all modifications and examples fairly falling within the scope of the appended claims either literally or under the doctrine of equivalents.
Claims (28)
1. A composite material, comprising:
a porous reinforced composite scaffold, comprising:
a polyaryletherketone polymer and anisometric reinforcement particles distributed throughout the polyaryletherketone polymer, and
a substantially continuously interconnected plurality of pores distributed throughout the polyaryletherketone polymer, each of the pores in the plurality of pores defined by voids interconnected by struts, each pore void having a size within a range from about 10 to 500 μm,
wherein a plurality of the anisometric reinforcement particles are both embedded within the polyaryletherketone polymer and exposed on the struts within the pore voids, and
wherein the porous reinforced composite scaffold has a scaffold volume that includes a material volume defined by the polyaryletherketone polymer and the anisometric reinforcement particles, and a pore volume defined by the plurality of pores.
2. The composite material according to claim 1 , wherein the porous reinforced composite scaffold is formed by mixing polymer, reinforcement, and porogen particles to obtain a substantially uniform particle mixture, compression molding the particle mixture, and removing the porogen particles.
3. The composite material according to claim 2 , wherein the particle mixture is dispersed in a non-solvating fluid, and wherein the non-solvating fluid is removed by one of vacuum, heating or a combination thereof prior to compression molding.
4. The composite material according to claim 2 , wherein each of the pores in the plurality of pores has a pore void size and shape defined by the removed porogen particles, and wherein the porogen particles are either homogenous or heterogeneous in shape and are either homogeneous or heterogeneous in size, the porogen particle size in the range from about 10 to 500 μm.
5. The composite material according to claim 2 , wherein the porogen particles are selected from the group consisting of NaCl, wax, polysaccharides, cellulose, and combinations thereof.
6. The composite material according to claim 2 , wherein the porogen particles have been removed from the porous reinforced composite scaffold material by leaching.
7. The composite material according to claim 1 , wherein the anisometric reinforcement particles are present in the polyaryletherketone polymer from about 1 to about 60% of the material volume.
8. The composite material according to claim 1 , wherein the anisometric reinforcement particles are distributed essentially uniformly throughout the polyaryletherketone polymer.
9. The composite material according to claim 1 , wherein the anisometric reinforcement particles comprise one or more of hydroxyapatite, calcium-deficient hydroxyapatite, carbonated calcium hydroxyapatite, beta-tricalcium phosphate (beta-TCP), alpha-tricalcium phosphate (alpha-TCP), amorphous calcium phosphate (ACP), octacalcium phosphate (OCP), tetracalcium phosphate, biphasic calcium phosphate (BCP), anhydrous dicalcium phosphate (DCPA), dicalcium phosphate dihydrate (DCPD), anhydrous monocalcium phosphate (MCPA), monocalcium phosphate monohydrate (MCPM), and combinations thereof, and, wherein the polyaryletherketone polymer comprises one or more of polyetheretherketone (PEEK), polyetherketonekteone (PEKK), and polyetherketone (PEK).
10. The composite material according to claim 1 , wherein the anisometric reinforcement particles comprise hydroxyapatite whiskers that have a mean aspect ratio (length along c-axis/length along a-axis) of greater than 1 and less than 100, and wherein the size of the anisometric reinforcement particles ranges between 20 nm and 2 mm.
11. The composite material according to claim 1 , wherein the pore volume ranges from about 1 to 95 percent, by volume, based on the scaffold volume.
12. The composite material according to claim 1 , wherein the porosity varies within the porous reinforced composite scaffold either from a highly porous center to a relatively dense exterior surface or from a relatively dense center to a highly porous exterior surface.
13. The composite material according to claim 1 , wherein the porous reinforced composite scaffold has a compressive elastic modulus similar to that of trabecular bone.
14. A composite material, comprising:
a porous reinforced composite scaffold, comprising:
a polyaryletherketone polymer and anisometric reinforcement particles comprising calcium phosphate crystals distributed essentially uniformly throughout the polyaryletherketone polymer, and
a substantially continuously interconnected plurality of pores that are uniformly distributed throughout the polyaryletherketone polymer, each of the pores in the plurality of pores defined by voids interconnected by struts, each pore void having a size within a range from about 10 to 500 μm, and
wherein the porous reinforced composite scaffold has a scaffold volume that includes a material volume defined by the polyaryletherketone polymer and the anisometric reinforcement particles, and a pore volume defined by the plurality of pores, and
wherein the anisometric reinforcement particles are present in the polyaryletherketone polymer from about 1 to about 60% of the material volume, and
wherein anisometric reinforcement particles are both embedded within the polyaryletherketone polymer and exposed on the struts within the pore voids, and
wherein the porous reinforced composite scaffold is formed by mixing polymer, reinforcement, and porogen particles to obtain a substantially uniform mixture, compression molding the particle mixture at a temperature from between 20 to 400 degrees C., and removing the porogen particles.
15. The composite material according to claim 14 , wherein the particle mixture is dispersed in a non-solvating fluid, and wherein the non-solvating fluid is removed by one of vacuum, heating or a combination thereof prior to compression molding.
16. The composite material according to claim 14 , wherein the compression molding temperature is in a range from about 350 to about 375 degrees C.
17. The composite material according to claim 14 , wherein the compression molding temperature is in a range from about 365 to about 375 degrees C.
18. A method for forming a porous reinforced composite scaffold, comprising:
using a powder processing approach in conjunction with compression molding and particle leaching to prepare the composite scaffold, the process including the steps comprising:
providing a powder mixture densified in a die, the powder mixture comprising a thermoplastic polymer powder, reinforcement particles in powder form, and porogen particles;
compression molding the densified powder mixture at a temperature sufficient to fuse the polymer powder to provide a sintered composite; and
removing the porogen particles a material from the porous reinforced composite scaffold.
19. The method for forming a porous reinforced composite scaffold according to claim 18 , further comprising the steps comprising;
prior to providing the powder mixture densified in a die, first providing each of the thermoplastic polymer powder, the reinforcement particles in powder form, and the porogen particles;
dispersing, in any order, each of the thermoplastic polymer powder, the reinforcement particles in powder form, and the porogen particles in a non-solvating fluid to provide a fluid dispersion of the powder mixture;
wet-consolidating the powder mixture to remove the fluid; and
drying the wet-consolidated powder mixture.
20. The method for forming a porous reinforced composite scaffold according to claim 18 , wherein the compression molding temperature sufficient to fuse the polymer powder is in a range from about 350 to about 375 degrees C.
21. The method for forming a porous reinforced composite scaffold according to claim 18 , wherein the compression molding temperature sufficient to fuse the polymer powder is in a range from about 365 to about 375 degrees C.
22. The method for forming a porous reinforced composite scaffold according to claim 18 , wherein the thermoplastic polymer powder comprises a polyaryletherketone polymer, and wherein the reinforcement particles comprise anisometric calcium phosphate.
23. A composite material, comprising:
a porous reinforced composite scaffold, comprising:
a thermoplastic polymer and reinforcement particles distributed throughout the thermoplastic polymer, and
a substantially continuously interconnected plurality of pores that are distributed throughout the thermoplastic polymer, each of the pores in the plurality of pores defined by voids interconnected by struts, each pore void having a size within a range from about 10 to 500 μm, and
wherein the porous reinforced composite scaffold has a scaffold volume that includes a material volume defined by the thermoplastic polymer and the reinforcement particles, and a pore volume defined by the plurality of pores, and
wherein the reinforcement particles are present in the thermoplastic polymer from about 1 to about 60% of the material volume, and
wherein reinforcement particles are both embedded within the thermoplastic polymer and exposed on the struts within the pore voids.
24. The composite material according to claim 23 , wherein the porous reinforced composite scaffold is formed by mixing thermoplastic polymer, reinforcement, and porogen particles to obtain a substantially uniform mixture, compression molding the particle mixture at a temperature from between 20 to 400 degrees C., and removing the porogen particles.
25. The composite material according to claim 23 , wherein the thermoplastic polymer is selected from the group consisting of a polyaryletherketone polymer, a bioresorbable polymer, and combinations thereof.
26. The composite material according to claim 23 , wherein the thermoplastic polymer is selected from the group consisting of polyaryletherketone (PAEK), polyetheretherketone (PEEK), polyetherketonekteone (PEKK), polyetherketone (PEK), polyethylene, high density polyethylene (HDPE), ultra-high molecular weight polyethylene (UHMWPE), low density polyethylene (LDPE), polyethylene oxide (PEO), polyurethane, polypropylene, polypropylene oxide (PPO), polysulfone, polypropylene, poly(DL-lactide) (PDLA), poly(L-lactide) (PLLA), poly(glycolide) (PGA), poly(c-caprolactone) (PCL), poly(dioxanone) (PDO), poly(glyconate), poly(hydroxybutyrate) (PHB), poly(hydroxyvalerate (PHV), poly(orthoesters), poly(carboxylates), poly(propylene fumarate), poly(phosphates), poly(carbonates), poly(anhydrides), poly(iminocarbonates), poly(phosphazenes), polymethylmethacrylate (PMMA), bisphenol a hydroxypropylmethacrylate (bis-GMA), tri(ethylene glycol) dimethacrylate (TEG-DMA), and combinations thereof.
27. The composite material according to claim 23 , wherein the reinforcement is selected from the group consisting of hydroxyapatite, calcium-deficient hydroxyapatite, carbonated calcium hydroxyapatite, beta-tricalcium phosphate (beta-TCP), alpha-tricalcium phosphate (alpha-TCP), amorphous calcium phosphate (ACP), octacalcium phosphate (OCP), tetracalcium phosphate, biphasic calcium phosphate (BCP), anhydrous dicalcium phosphate (DCPA), dicalcium phosphate dihydrate (DCPD), anhydrous monocalcium phosphate (MCPA), monocalcium phosphate monohydrate (MCPM), and combinations thereof.
28. The composite material according to claim 23 , wherein the thermoplastic polymer comprises a polyaryletherketone polymer, and wherein the reinforcement comprises anisometric calcium phosphate.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/180,935 US20210177620A1 (en) | 2007-02-28 | 2021-02-22 | Porous composite biomaterials and related methods |
US17/519,336 US20220062004A1 (en) | 2007-02-28 | 2021-11-04 | Porous composite biomaterials and related methods |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90409807P | 2007-02-28 | 2007-02-28 | |
US93925607P | 2007-05-21 | 2007-05-21 | |
US12/039,666 US20080206297A1 (en) | 2007-02-28 | 2008-02-28 | Porous composite biomaterials and related methods |
US14/078,614 US10945854B2 (en) | 2007-02-28 | 2013-11-13 | Porous composite biomaterials and related methods |
US17/180,935 US20210177620A1 (en) | 2007-02-28 | 2021-02-22 | Porous composite biomaterials and related methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/078,614 Continuation US10945854B2 (en) | 2007-02-28 | 2013-11-13 | Porous composite biomaterials and related methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/519,336 Continuation US20220062004A1 (en) | 2007-02-28 | 2021-11-04 | Porous composite biomaterials and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210177620A1 true US20210177620A1 (en) | 2021-06-17 |
Family
ID=39716166
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/039,666 Abandoned US20080206297A1 (en) | 2007-02-28 | 2008-02-28 | Porous composite biomaterials and related methods |
US14/078,614 Active 2028-06-06 US10945854B2 (en) | 2007-02-28 | 2013-11-13 | Porous composite biomaterials and related methods |
US17/180,935 Abandoned US20210177620A1 (en) | 2007-02-28 | 2021-02-22 | Porous composite biomaterials and related methods |
US17/519,336 Pending US20220062004A1 (en) | 2007-02-28 | 2021-11-04 | Porous composite biomaterials and related methods |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/039,666 Abandoned US20080206297A1 (en) | 2007-02-28 | 2008-02-28 | Porous composite biomaterials and related methods |
US14/078,614 Active 2028-06-06 US10945854B2 (en) | 2007-02-28 | 2013-11-13 | Porous composite biomaterials and related methods |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/519,336 Pending US20220062004A1 (en) | 2007-02-28 | 2021-11-04 | Porous composite biomaterials and related methods |
Country Status (2)
Country | Link |
---|---|
US (4) | US20080206297A1 (en) |
WO (1) | WO2008106625A2 (en) |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6558426B1 (en) | 2000-11-28 | 2003-05-06 | Medidea, Llc | Multiple-cam, posterior-stabilized knee prosthesis |
GB0329654D0 (en) | 2003-12-23 | 2004-01-28 | Smith & Nephew | Tunable segmented polyacetal |
EP1988855A2 (en) | 2006-02-27 | 2008-11-12 | Synthes GmbH | Intervertebral implant with fixation geometry |
US20110282392A1 (en) * | 2006-10-30 | 2011-11-17 | Tissue Regeneration Systems, Inc. | Degradable cage for bone fusion |
DE602007011671D1 (en) | 2006-11-30 | 2011-02-10 | Smith & Nephew Inc | FIBER REINFORCED COMPOSITE MATERIAL |
US11179243B2 (en) | 2007-02-28 | 2021-11-23 | Happe Spine Llc | Implantable devices |
US20080206297A1 (en) | 2007-02-28 | 2008-08-28 | Roeder Ryan K | Porous composite biomaterials and related methods |
EP2142353A1 (en) | 2007-04-18 | 2010-01-13 | Smith & Nephew PLC | Expansion moulding of shape memory polymers |
JP5680957B2 (en) | 2007-04-19 | 2015-03-04 | スミス アンド ネフュー インコーポレーテッドSmith & Nephew,Inc. | Graft fixation |
JP5520814B2 (en) | 2007-04-19 | 2014-06-11 | スミス アンド ネフュー インコーポレーテッド | Multimodal shape memory polymer |
US20110035017A1 (en) * | 2007-09-25 | 2011-02-10 | Depuy Products, Inc. | Prosthesis with cut-off pegs and surgical method |
US8632600B2 (en) | 2007-09-25 | 2014-01-21 | Depuy (Ireland) | Prosthesis with modular extensions |
US8128703B2 (en) | 2007-09-28 | 2012-03-06 | Depuy Products, Inc. | Fixed-bearing knee prosthesis having interchangeable components |
US8715359B2 (en) | 2009-10-30 | 2014-05-06 | Depuy (Ireland) | Prosthesis for cemented fixation and method for making the prosthesis |
US9204967B2 (en) | 2007-09-28 | 2015-12-08 | Depuy (Ireland) | Fixed-bearing knee prosthesis having interchangeable components |
CA2711403C (en) * | 2008-02-01 | 2016-08-09 | Synthes Usa, Llc | Porous biocompatible polymer material and methods |
US9168145B2 (en) | 2008-06-30 | 2015-10-27 | Depuy (Ireland) | Posterior stabilized orthopaedic knee prosthesis having controlled condylar curvature |
US8187335B2 (en) | 2008-06-30 | 2012-05-29 | Depuy Products, Inc. | Posterior stabilized orthopaedic knee prosthesis having controlled condylar curvature |
US8828086B2 (en) | 2008-06-30 | 2014-09-09 | Depuy (Ireland) | Orthopaedic femoral component having controlled condylar curvature |
US9119723B2 (en) | 2008-06-30 | 2015-09-01 | Depuy (Ireland) | Posterior stabilized orthopaedic prosthesis assembly |
US8192498B2 (en) | 2008-06-30 | 2012-06-05 | Depuy Products, Inc. | Posterior cructiate-retaining orthopaedic knee prosthesis having controlled condylar curvature |
US8236061B2 (en) | 2008-06-30 | 2012-08-07 | Depuy Products, Inc. | Orthopaedic knee prosthesis having controlled condylar curvature |
US8206451B2 (en) | 2008-06-30 | 2012-06-26 | Depuy Products, Inc. | Posterior stabilized orthopaedic prosthesis |
EP2349107B1 (en) | 2008-08-14 | 2016-12-21 | Oxford Performance Materials, Inc. | Customized implants for bone replacement |
CN102256570B (en) * | 2008-11-07 | 2015-09-02 | 斯恩蒂斯有限公司 | The interpyramidal distance piece of vertebra and connecting plate assembly |
WO2010091223A1 (en) * | 2009-02-06 | 2010-08-12 | David Cheung | Biphasic collagen membrane or capsule for guided tissue regeneration |
US20100256758A1 (en) * | 2009-04-02 | 2010-10-07 | Synvasive Technology, Inc. | Monolithic orthopedic implant with an articular finished surface |
US8609127B2 (en) * | 2009-04-03 | 2013-12-17 | Warsaw Orthopedic, Inc. | Medical implant with bioactive material and method of making the medical implant |
US9492587B2 (en) * | 2009-04-13 | 2016-11-15 | Abbott Cardiovascular Systems Inc. | Stent made from an ultra high molecular weight bioabsorbable polymer with high fatigue and fracture resistance |
US20100262244A1 (en) * | 2009-04-14 | 2010-10-14 | Warsaw Orthopedic, Inc. | Metal Coated Implant |
US9399086B2 (en) | 2009-07-24 | 2016-07-26 | Warsaw Orthopedic, Inc | Implantable medical devices |
US9039784B2 (en) * | 2009-07-28 | 2015-05-26 | Southwest Research Institute | Micro-structure particles for load bearing bone growth |
EP2606857A1 (en) | 2009-10-30 | 2013-06-26 | DePuy Products, Inc. | Prosthesis with composite component |
US9011547B2 (en) | 2010-01-21 | 2015-04-21 | Depuy (Ireland) | Knee prosthesis system |
KR101196062B1 (en) | 2010-05-03 | 2012-11-01 | 순천향대학교 산학협력단 | Method for preparing porous biphasic calciumphosphate granules |
EP2621869A4 (en) * | 2010-10-01 | 2014-10-08 | Skeletal Kinetics Llc | Porogen containing calcium phosphate cement compositions |
US9339387B2 (en) | 2010-10-13 | 2016-05-17 | Cibor, Inc. | Synthetic bone grafts constructed from carbon foam materials |
US8998987B2 (en) | 2010-11-11 | 2015-04-07 | Zimmer, Inc. | Orthopedic implant with porous polymer bone contacting surface |
WO2012088238A2 (en) | 2010-12-21 | 2012-06-28 | Synthes Usa, Llc | Intervertebral implants, systems, and methods of use |
WO2012099852A1 (en) | 2011-01-17 | 2012-07-26 | Cibor, Inc. | Reinforced carbon fiber/carbon foam intervertebral spine fusion device |
GB201100815D0 (en) * | 2011-01-18 | 2011-03-02 | Invibio Ltd | Polymeric materials |
GB2488111A (en) * | 2011-02-14 | 2012-08-22 | Invibio Ltd | Components incorporating bioactive material |
DE102011004305A1 (en) * | 2011-02-17 | 2012-08-23 | Evonik Degussa Gmbh | Process for the production of bars |
JP5955326B2 (en) * | 2011-08-30 | 2016-07-20 | 国立大学法人京都大学 | Porous scaffold material and method for producing the same |
CN103959359A (en) * | 2011-10-03 | 2014-07-30 | 克利夫兰临床医学基金会 | Synthetic bone model and method for providing same |
DE102011119939A1 (en) * | 2011-12-01 | 2013-06-06 | Technische Universität Hamburg-Harburg | Method of making a composite, the composite and the use of the composite to make certain products |
US11304811B2 (en) | 2012-01-17 | 2022-04-19 | KYOCERA Medical Technologies, Inc. | Surgical implant devices incorporating porous surfaces and associated method of manufacture |
KR20150015532A (en) * | 2012-05-30 | 2015-02-10 | 뉴욕 유니버시티 | Tissue repair devices and scaffolds |
US10207027B2 (en) | 2012-06-11 | 2019-02-19 | Globus Medical, Inc. | Bioactive bone graft substitutes |
CN102727937B (en) * | 2012-06-28 | 2014-03-26 | 哈尔滨工程大学 | Biodegradable zinc (or zinc alloy) and porous biphase calcium phosphate composite material and preparation method thereof |
US8843229B2 (en) * | 2012-07-20 | 2014-09-23 | Biomet Manufacturing, Llc | Metallic structures having porous regions from imaged bone at pre-defined anatomic locations |
EP3431271B1 (en) | 2012-08-21 | 2020-08-05 | Vertera Inc. | Method of forming porous polymeric particulates |
US9949837B2 (en) * | 2013-03-07 | 2018-04-24 | Howmedica Osteonics Corp. | Partially porous bone implant keel |
US20140342013A1 (en) * | 2013-03-14 | 2014-11-20 | Skeletal Kinetics, Llc | Calcium phosphate cement compositions that set into high strength porous structures |
EP3024419B1 (en) * | 2013-07-24 | 2022-05-11 | Kyocera Medical Technologies, Inc. | Surgical implant devices incorporating porous surfaces |
WO2015013479A2 (en) | 2013-07-24 | 2015-01-29 | Renovis Surgical Technologies, Inc. | Surgical implant devices incorporating porous surfaces |
US9550012B2 (en) | 2013-08-05 | 2017-01-24 | University Of Notre Dame Du Lac | Tissue scaffolds having bone growth factors |
US9295565B2 (en) | 2013-10-18 | 2016-03-29 | Spine Wave, Inc. | Method of expanding an intradiscal space and providing an osteoconductive path during expansion |
US9504550B2 (en) | 2014-06-26 | 2016-11-29 | Vertera, Inc. | Porous devices and processes for producing same |
US9498922B2 (en) | 2014-06-26 | 2016-11-22 | Vertera, Inc. | Apparatus and process for producing porous devices |
JP6871855B2 (en) * | 2014-10-14 | 2021-05-19 | サムエル リンチ, | Composition for treating wounds |
US9867718B2 (en) | 2014-10-22 | 2018-01-16 | DePuy Synthes Products, Inc. | Intervertebral implants, systems, and methods of use |
US10279081B2 (en) | 2014-10-24 | 2019-05-07 | Allosource | Composite grafts, systems, and methods |
US20160167306A1 (en) * | 2014-12-11 | 2016-06-16 | Massachusetts Institute Of Technology | Systems and methods of hierarchical material design for additive fabrication |
US9821339B2 (en) * | 2014-12-19 | 2017-11-21 | Palo Alto Research Center Incorporated | System and method for digital fabrication of graded, hierarchical material structures |
US9486960B2 (en) | 2014-12-19 | 2016-11-08 | Palo Alto Research Center Incorporated | System for digital fabrication of graded, hierarchical material structures |
WO2016105286A1 (en) * | 2014-12-25 | 2016-06-30 | Hasirci Vasif Nejat | A new prosthesis material developed for use in the treatment of cervical and lumbar disc hernia |
EP3240584A1 (en) * | 2014-12-29 | 2017-11-08 | Hasirci, Vasif Nejat | Craniofacial implants |
CN104623728B (en) * | 2015-01-12 | 2016-05-11 | 四川大学 | Anisotropy bone replacement composites of a kind of injection mo(u)lding and preparation method thereof |
AU2016219150B2 (en) * | 2015-02-13 | 2020-06-25 | Eit Emerging Implant Technologies Gmbh | Spinal implants with engineered cellular structure and internal imaging markers |
USD815281S1 (en) | 2015-06-23 | 2018-04-10 | Vertera, Inc. | Cervical interbody fusion device |
FR3039988A1 (en) * | 2015-08-11 | 2017-02-17 | Abdelmadjid Djemai | EXPANDED SPRING INTERSOMATIC CAGE, DOUBLE-STRUCKED DOUBLE STRUCK HINGE AND METHOD FOR MANUFACTURING THE SAME |
US10485897B2 (en) * | 2015-10-12 | 2019-11-26 | Erik Erbe | Osteogenic and angiogenic implant material |
CN105233335B (en) * | 2015-11-06 | 2018-07-13 | 四川大学 | Biologically active porous poly(aryl ether ketone) material of one kind and the preparation method and application thereof |
US10596660B2 (en) * | 2015-12-15 | 2020-03-24 | Howmedica Osteonics Corp. | Porous structures produced by additive layer manufacturing |
EP3389570B1 (en) * | 2015-12-16 | 2024-04-17 | Nuvasive, Inc. | Porous spinal fusion implant |
CN106913406A (en) * | 2015-12-25 | 2017-07-04 | 苏州微创脊柱创伤医疗科技有限公司 | A kind of spinal fusion device and preparation method thereof |
CN105559950B (en) * | 2016-02-03 | 2018-02-02 | 北京纳通科技集团有限公司 | Fusion device |
AU2017232908A1 (en) * | 2016-03-18 | 2018-10-11 | Allosource | Composite medical grafts and methods of use and manufacture |
US20190076577A1 (en) * | 2016-03-18 | 2019-03-14 | Allosource | Composite medical grafts and methods of use and manufacture |
DE102016107223B4 (en) * | 2016-04-19 | 2018-05-24 | Karl Leibinger Medizintechnik Gmbh & Co. Kg | Hybrid implant made of a composite material |
US11638645B2 (en) | 2016-05-19 | 2023-05-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biomimetic plywood motifs for bone tissue engineering |
US10806586B2 (en) * | 2016-05-19 | 2020-10-20 | University Of Pittsburgh—Of The Commonwealth System Of Higer Education | Biomimetic plywood motifs for bone tissue engineering |
US10660764B2 (en) * | 2016-06-14 | 2020-05-26 | The Trustees Of The Stevens Institute Of Technology | Load sustaining bone scaffolds for spinal fusion utilizing hyperbolic struts and translational strength gradients |
FI127762B (en) * | 2016-09-19 | 2019-02-15 | Tty Saeaetioe | Method for producing porous composite material |
US11033394B2 (en) * | 2016-10-25 | 2021-06-15 | Institute for Musculoskeletal Science and Education, Ltd. | Implant with multi-layer bone interfacing lattice |
CN106344221A (en) * | 2016-10-26 | 2017-01-25 | 四川大学 | Bonelike porous biomechanical bionic designed spinal fusion device and preparation method and use thereof |
CN106435544A (en) * | 2016-11-09 | 2017-02-22 | 北京科技大学 | Method for preparing nano-hydroxyapatite gradient coating on titanium alloy matrix |
US11685113B2 (en) * | 2017-03-06 | 2023-06-27 | Katholieke Universiteit Leuven | 3D printing of porous liquid handling device |
GB2560369B (en) * | 2017-03-10 | 2020-04-01 | Vestlandets Innovasjonsselskap As | Tissue engineering scaffolds |
WO2018165571A1 (en) * | 2017-03-10 | 2018-09-13 | Life Spine, Inc. (A Delaware Corporation) | 3-d printed orthopedic implants |
US10064726B1 (en) | 2017-04-18 | 2018-09-04 | Warsaw Orthopedic, Inc. | 3D printing of mesh implants for bone delivery |
US20180296343A1 (en) * | 2017-04-18 | 2018-10-18 | Warsaw Orthopedic, Inc. | 3-d printing of porous implants |
US11660196B2 (en) | 2017-04-21 | 2023-05-30 | Warsaw Orthopedic, Inc. | 3-D printing of bone grafts |
US20180339082A1 (en) * | 2017-05-23 | 2018-11-29 | Bioalpha Corporation | Polyether ether ketone surface-modified with hydroxyapatite |
CN107320220B (en) * | 2017-06-14 | 2019-12-24 | 西安交通大学 | Preparation method of porous implant based on ceramic additive manufacturing |
US11628517B2 (en) | 2017-06-15 | 2023-04-18 | Howmedica Osteonics Corp. | Porous structures produced by additive layer manufacturing |
EP3479798B1 (en) | 2017-11-03 | 2023-06-21 | Howmedica Osteonics Corp. | Flexible construct for femoral reconstruction |
US10713238B2 (en) * | 2017-11-14 | 2020-07-14 | Snowflake Inc. | Database metadata in immutable storage |
CN108309517B (en) * | 2018-01-25 | 2019-08-30 | 中国人民解放军新疆军区总医院 | A kind of absorbable cervical fusion cage and preparation method thereof |
USD870888S1 (en) | 2018-03-02 | 2019-12-24 | Restor3D, Inc. | Accordion airway stent |
USD870889S1 (en) | 2018-03-02 | 2019-12-24 | Restor3D, Inc. | Cutout airway stent |
USD870890S1 (en) | 2018-03-02 | 2019-12-24 | Restor3D, Inc. | Spiral airway stent |
US10183442B1 (en) | 2018-03-02 | 2019-01-22 | Additive Device, Inc. | Medical devices and methods for producing the same |
USD871577S1 (en) | 2018-03-02 | 2019-12-31 | Restor3D, Inc. | Studded airway stent |
WO2019191149A1 (en) * | 2018-03-26 | 2019-10-03 | The Regents Of The University Of California | Medical implants and other articles of manufacture based on trabecular bone lattices |
US10947419B2 (en) | 2018-07-23 | 2021-03-16 | Palo Alto Research Center Incorporated | Method for joining dissimilar materials |
WO2020060809A1 (en) * | 2018-09-17 | 2020-03-26 | Rejuvablast LLC | Combination grafts for tissue repair or regeneration applications |
WO2020061176A1 (en) * | 2018-09-18 | 2020-03-26 | Happe Spine Llc | Implantable devices |
US11607476B2 (en) | 2019-03-12 | 2023-03-21 | Happe Spine Llc | Implantable medical device with thermoplastic composite body and method for forming thermoplastic composite body |
US10889053B1 (en) | 2019-03-25 | 2021-01-12 | Restor3D, Inc. | Custom surgical devices and method for manufacturing the same |
USD920517S1 (en) | 2020-01-08 | 2021-05-25 | Restor3D, Inc. | Osteotomy wedge |
USD920515S1 (en) | 2020-01-08 | 2021-05-25 | Restor3D, Inc. | Spinal implant |
US10772732B1 (en) | 2020-01-08 | 2020-09-15 | Restor3D, Inc. | Sheet based triply periodic minimal surface implants for promoting osseointegration and methods for producing same |
USD920516S1 (en) | 2020-01-08 | 2021-05-25 | Restor3D, Inc. | Osteotomy wedge |
CN112060574B (en) * | 2020-07-21 | 2022-03-29 | 陈勃生 | Additive manufacturing method of three-dimensional implant made of biological composite material |
EP4210922A1 (en) | 2020-09-11 | 2023-07-19 | Happe Spine LLC | Method for forming an implantable medical device with varied composition and porosity |
EP3984715B1 (en) * | 2020-10-13 | 2023-11-15 | Technische Universität München | Fiber-reinforced soluble core and method for its manufacture |
EP3984501A1 (en) * | 2020-10-14 | 2022-04-20 | Warsaw Orthopedic, Inc. | Additive-manufactured non-woven fibrous implants, systems, and related manufacturing methods |
US20220203589A1 (en) * | 2020-12-24 | 2022-06-30 | Next Chapter Manufacturing Corporation | Vented Mold Pin |
US20220296780A1 (en) * | 2021-03-16 | 2022-09-22 | Orthomod Llc | Bioceramic-containing thermoplastic extrusion and method of surgical implant manufacture |
CN113103576B (en) * | 2021-04-07 | 2022-01-28 | 吉林大学 | 3D printing method for ordered gradient porous material |
CN113842499B (en) * | 2021-09-17 | 2022-07-01 | 中国科学院宁波材料技术与工程研究所 | Ultrahigh molecular weight polyethylene composite material and preparation method and application thereof |
WO2023137124A2 (en) * | 2022-01-12 | 2023-07-20 | Orthofundamentals, Llc | Medical implants for generating fusion between two bones |
CN115120781A (en) * | 2022-07-11 | 2022-09-30 | 运怡(北京)医疗器械有限公司 | Medical composite high polymer material and preparation method thereof |
US11850144B1 (en) | 2022-09-28 | 2023-12-26 | Restor3D, Inc. | Ligament docking implants and processes for making and using same |
US11806028B1 (en) | 2022-10-04 | 2023-11-07 | Restor3D, Inc. | Surgical guides and processes for producing and using the same |
EP4353168A1 (en) * | 2022-10-12 | 2024-04-17 | Kumovis GmbH | 3d printed semi-finished part for medical implant manufacturing and medical implant thereof |
US11960266B1 (en) | 2023-08-23 | 2024-04-16 | Restor3D, Inc. | Patient-specific medical devices and additive manufacturing processes for producing the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020115742A1 (en) * | 2001-02-22 | 2002-08-22 | Trieu Hai H. | Bioactive nanocomposites and methods for their use |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514378A (en) * | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US6689608B1 (en) * | 1993-02-01 | 2004-02-10 | Massachusetts Institute Of Technology | Porous biodegradable polymeric materials for cell transplantation |
US5522895A (en) * | 1993-07-23 | 1996-06-04 | Rice University | Biodegradable bone templates |
US5626861A (en) * | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
WO1997010010A1 (en) * | 1995-09-14 | 1997-03-20 | Takiron Co., Ltd. | Osteosynthetic material, composited implant material, and process for preparing the same |
US5866155A (en) * | 1996-11-20 | 1999-02-02 | Allegheny Health, Education And Research Foundation | Methods for using microsphere polymers in bone replacement matrices and composition produced thereby |
US6472210B1 (en) * | 1997-11-14 | 2002-10-29 | Bonetec Corporation | Polymer scaffold having microporous polymer struts defining interconnected macropores |
US7022522B2 (en) * | 1998-11-13 | 2006-04-04 | Limin Guan | Macroporous polymer scaffold containing calcium phosphate particles |
US6306424B1 (en) * | 1999-06-30 | 2001-10-23 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
US6333029B1 (en) * | 1999-06-30 | 2001-12-25 | Ethicon, Inc. | Porous tissue scaffoldings for the repair of regeneration of tissue |
US6355699B1 (en) * | 1999-06-30 | 2002-03-12 | Ethicon, Inc. | Process for manufacturing biomedical foams |
WO2001028469A2 (en) * | 1999-10-21 | 2001-04-26 | Sdgi Holdings, Inc. | Devices and techniques for a posterior lateral disc space approach |
US7758882B2 (en) * | 2000-01-31 | 2010-07-20 | Indiana University Research And Technology Corporation | Composite biomaterial including anisometric calcium phosphate reinforcement particles and related methods |
AU2001261465A1 (en) * | 2000-05-12 | 2001-11-26 | The Regents Of The University Of Michigan | Reverse fabrication of porous materials |
US6423252B1 (en) * | 2000-06-23 | 2002-07-23 | Ethicon, Inc. | Methods of making micropatterned foams |
JP2004501719A (en) * | 2000-07-03 | 2004-01-22 | オステオテック インコーポレーテッド | Osteogenic implants derived from bone |
US6595998B2 (en) * | 2001-03-08 | 2003-07-22 | Spinewave, Inc. | Tissue distraction device |
US20050177238A1 (en) * | 2001-05-01 | 2005-08-11 | Khandkar Ashok C. | Radiolucent bone graft |
US6987136B2 (en) * | 2001-07-13 | 2006-01-17 | Vita Special Purpose Corporation | Bioactive spinal implant material and method of manufacture thereof |
US7037339B2 (en) * | 2001-09-27 | 2006-05-02 | Zimmer Spine, Inc. | Modular spinal fusion device |
US6712850B2 (en) * | 2001-11-30 | 2004-03-30 | Ethicon, Inc. | Porous tissue scaffolds for the repair and regeneration of dermal tissue |
EP1344538A1 (en) * | 2002-03-14 | 2003-09-17 | Degradable Solutions AG | Porous biodegradable implant material and method for its fabrication |
US6991653B2 (en) * | 2002-03-21 | 2006-01-31 | Sdgi Holdings, Inc. | Vertebral body and disc space replacement devices |
US6758862B2 (en) * | 2002-03-21 | 2004-07-06 | Sdgi Holdings, Inc. | Vertebral body and disc space replacement devices |
US20040002770A1 (en) * | 2002-06-28 | 2004-01-01 | King Richard S. | Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof |
US7049348B2 (en) * | 2002-07-06 | 2006-05-23 | Kensey Nash Corporation | Resorbable structure for treating and healing of tissue defects |
US20050251267A1 (en) | 2004-05-04 | 2005-11-10 | John Winterbottom | Cell permeable structural implant |
US20040193270A1 (en) * | 2003-03-31 | 2004-09-30 | Depuyacromed, Inc. | Implantable bone graft |
US6887408B2 (en) * | 2003-05-05 | 2005-05-03 | Porogen Llc | Porous poly(aryl ether ketone) membranes, processes for their preparation and use thereof |
WO2005032418A2 (en) | 2003-10-01 | 2005-04-14 | University Of Washington | Novel porous biomaterials |
US20050100578A1 (en) | 2003-11-06 | 2005-05-12 | Schmid Steven R. | Bone and tissue scaffolding and method for producing same |
US7837732B2 (en) * | 2003-11-20 | 2010-11-23 | Warsaw Orthopedic, Inc. | Intervertebral body fusion cage with keels and implantation methods |
US20050149192A1 (en) * | 2003-11-20 | 2005-07-07 | St. Francis Medical Technologies, Inc. | Intervertebral body fusion cage with keels and implantation method |
US7666230B2 (en) * | 2003-12-08 | 2010-02-23 | Depuy Products, Inc. | Implant device for cartilage regeneration in load bearing articulation regions |
US7137997B2 (en) * | 2003-12-29 | 2006-11-21 | Globus Medical, Inc. | Spinal fusion implant |
US7189263B2 (en) * | 2004-02-03 | 2007-03-13 | Vita Special Purpose Corporation | Biocompatible bone graft material |
US7905920B2 (en) * | 2004-08-19 | 2011-03-15 | Foster-Miller, Inc. | Support system for intervertebral fusion |
US7176273B2 (en) * | 2004-11-03 | 2007-02-13 | Porogen Llc | Functionalized porous poly(aryl ether ketone) materials and their use |
US7780732B2 (en) * | 2005-03-16 | 2010-08-24 | Dennis Lee Abernathie | Spinal fusion cage and method of use |
US8057548B2 (en) * | 2005-03-16 | 2011-11-15 | Dennis Lee Abernathie | Spinal fusion cage, method of design, and method of use |
WO2006113642A1 (en) | 2005-04-18 | 2006-10-26 | Duke University | Three-dimensional fiber scaffolds for tissue engineering |
US7687098B1 (en) | 2005-08-26 | 2010-03-30 | Charlie W. Chi | Chemical mechanical vapor deposition device for production of bone substitute material |
CA2627895C (en) | 2005-11-04 | 2014-10-14 | Ppd Meditech | Porous material and method for fabricating same |
GB0604061D0 (en) | 2006-03-01 | 2006-04-12 | Invibio Ltd | Polymetric materials |
DE102006041023B4 (en) | 2006-09-01 | 2014-06-12 | Biocer Entwicklungs Gmbh | Structured coatings for implants and process for their preparation |
CA2667000A1 (en) | 2006-09-25 | 2008-04-03 | James P. Murphy | Bioactive load-bearing composites comprising peek and bioglass particles |
US20080161927A1 (en) * | 2006-10-18 | 2008-07-03 | Warsaw Orthopedic, Inc. | Intervertebral Implant with Porous Portions |
US20080206297A1 (en) | 2007-02-28 | 2008-08-28 | Roeder Ryan K | Porous composite biomaterials and related methods |
CA2680586A1 (en) | 2007-03-26 | 2008-10-02 | Mei Wei | Electrospun apatite/polymer nano-composite scaffolds |
US20110035018A1 (en) | 2007-09-25 | 2011-02-10 | Depuy Products, Inc. | Prosthesis with composite component |
WO2009095960A1 (en) | 2008-01-28 | 2009-08-06 | Ngk Spark Plug Co., Ltd. | Surface foamed article, biological implant and method of producing the same |
CA2711403C (en) | 2008-02-01 | 2016-08-09 | Synthes Usa, Llc | Porous biocompatible polymer material and methods |
GB0813093D0 (en) | 2008-07-17 | 2008-08-27 | Invibio Ltd | Polymeric materials |
WO2010009390A2 (en) | 2008-07-18 | 2010-01-21 | North Carolina State University | Processing of biocompatible coating on polymeric implants |
GB0818156D0 (en) | 2008-10-03 | 2008-11-12 | Smith & Nephew Orthopaedics Ag | Plasma spray process and products formed thereby |
GB0819055D0 (en) | 2008-10-17 | 2008-11-26 | Invibio Ltd | Polymeric materials |
US20100145393A1 (en) | 2008-12-05 | 2010-06-10 | Medicinelodge, Inc. | Medical and dental porous implants |
US20100168798A1 (en) | 2008-12-30 | 2010-07-01 | Clineff Theodore D | Bioactive composites of polymer and glass and method for making same |
US8609127B2 (en) | 2009-04-03 | 2013-12-17 | Warsaw Orthopedic, Inc. | Medical implant with bioactive material and method of making the medical implant |
GB2469991B (en) | 2009-04-21 | 2013-08-07 | Invibio Ltd | Polymeric materials |
CA2762903C (en) | 2009-05-22 | 2013-07-30 | Soft Tissue Regeneration, Inc. | Mechanically competent scaffold for ligament and tendon regeneration |
DE102009026622A1 (en) | 2009-05-29 | 2010-12-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Shaped bodies with embedded coupling particles for biomolecules |
US9399086B2 (en) | 2009-07-24 | 2016-07-26 | Warsaw Orthopedic, Inc | Implantable medical devices |
US8226725B2 (en) | 2009-09-01 | 2012-07-24 | Howmedica Osteonics Corp. | Prosthesis having a soft tissue attachment element |
EP2338532B1 (en) | 2009-12-23 | 2018-01-10 | Fundacion Inasmet | Porous PEEK article as an implant |
GB201005122D0 (en) | 2010-03-26 | 2010-05-12 | Invibio Ltd | Medical device |
GB2488111A (en) | 2011-02-14 | 2012-08-22 | Invibio Ltd | Components incorporating bioactive material |
GB201104805D0 (en) | 2011-03-22 | 2011-05-04 | Invibio Ltd | Medical device |
GB201110729D0 (en) | 2011-06-24 | 2011-08-10 | Invibio Ltd | Polymeric materials |
GB201120375D0 (en) | 2011-11-25 | 2012-01-11 | Invibio Ltd | Prosthodontic device |
GB201219686D0 (en) | 2012-11-01 | 2012-12-12 | Invibio Ltd | Orthopaedic polymer-on-polymer bearings |
US8829096B2 (en) | 2013-02-08 | 2014-09-09 | Invibio Limited | Polymeric materials |
-
2008
- 2008-02-28 US US12/039,666 patent/US20080206297A1/en not_active Abandoned
- 2008-02-28 WO PCT/US2008/055391 patent/WO2008106625A2/en active Application Filing
-
2013
- 2013-11-13 US US14/078,614 patent/US10945854B2/en active Active
-
2021
- 2021-02-22 US US17/180,935 patent/US20210177620A1/en not_active Abandoned
- 2021-11-04 US US17/519,336 patent/US20220062004A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020115742A1 (en) * | 2001-02-22 | 2002-08-22 | Trieu Hai H. | Bioactive nanocomposites and methods for their use |
Non-Patent Citations (1)
Title |
---|
Goldstein, S., J. Biomechanics 20(11): 1055 – 1066 (1987). (Year: 1987) * |
Also Published As
Publication number | Publication date |
---|---|
US20210015977A9 (en) | 2021-01-21 |
US20080206297A1 (en) | 2008-08-28 |
US20220062004A1 (en) | 2022-03-03 |
WO2008106625A3 (en) | 2009-12-30 |
WO2008106625A2 (en) | 2008-09-04 |
US10945854B2 (en) | 2021-03-16 |
US20140236299A1 (en) | 2014-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210177620A1 (en) | Porous composite biomaterials and related methods | |
US11179243B2 (en) | Implantable devices | |
US11911535B2 (en) | Implantable medical device with thermoplastic composite body and method for forming thermoplastic composite body | |
US8715286B2 (en) | Porous and nonporous materials for tissue grafting and repair | |
EP1024841B1 (en) | Bone substitutes | |
EP1357863B1 (en) | Compositions and methods for biomedical applications | |
US20150265745A1 (en) | Porous and Nonporous Materials for Tissue Grafting and Repair | |
WO2020061176A1 (en) | Implantable devices | |
US10105207B2 (en) | Porous and nonporous materials for tissue grafting and repair | |
Dunkley | The Development and Characterization of a Primarily Mineral Calcium Phosphate-Poly (ε-caprolactone) Biocomposite | |
Vaidyanathan et al. | Resorbable Polymer‐Ceramic Composites for Orthopedic Scaffold Applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |